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ABSTRACT OF THE THESIS
BIOHAZARD NEUTRALIZATION BASED ON LIPID TECHNOLOGY

by
Edelmira Bosques
Florida International University, 2008
Miami, Florida
Professor Eric T. Crumpler, Major Professor
A rapid detection and neutralization method for biowarfare agents would be a
great biodefense in war times. With this purpose, liposomes were developed following
the lipid film formation, rehydration, and extrusion procedure as the production method.
MgOCl 2 was encapsulated in the liposomes and it was tested with three different
bacterium B. cereus; B. thuringiensis; and B. subtilis. For specificity, the liposomes were
modified with a polyclonal antibody against B. cereus and B. subtilis. The liposomes
were characterized using a Malvern Zetasizer Instrument, and the study revealed stability
of the liposomes stored at 4*C for a period of 15 days.

A live/dead assay revealed a

significant reduction of bacterium incubated with MgOCl2-liposomes. Smaller reduction
percentages, but yet significant, were observed with the MgOCl 2-immunoliposomes.

A

colony growth assay revealed a significant reduction percentage for empty liposomes,
MgOCl2-liposomes, and MgOCl 2 -immunoliposomes incubated with B. thuringiensis.
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1.0 INTRODUCTION
Beginning on September 18, 2001, several mailed letters containing Bacillus
anthracis(B. anthracis)spores were received at New York and Florida, by some media
organizations.

In October 2001, some members of the U.S. Congress also received

mailed letters containing B. anthracisspores. Due to the B. anthracisintentional delivery
in October 2001; 22 cases of pulmonary anthrax, caused by the inhalation of B. anthracis
spores were reported. Five of the patients died due to a misdiagnosis of the disease (John
A. Jernigan, Stephens et al. 2001). B. anthracisspores are acquired by the host through
breaks in the skin, by inhalation or by ingestion (Committee to Update Science). It can
cause different types of infections, which, if not detected before the fatal stage it will kill
the host. The ease of spreading this bacteria spore as an aerosol, with the purpose of
causing a massive infection, is attractive to terrorists. In addition, the spores are resistant
to environmental changes and can persist in the environment for long periods, causing
massive infections. Since all members of the Bacillus genus produce the endospores as
part of their life cycle, it is impossible to determine the identity of the spores by casual or
morphological examination (Swiecki 2006).

In case of a bioattack, a fast and accurate

way of neutralization is needed to prevent a massive infection.
In this study, liposomes were used as drug carriers of a bacterial neutralizing
agent magnesium oxide chlorine (MgOCl 2 ) with the purpose of enhancing the
bactericidal effect of MgOCl 2 on bacterium, aiming the use of this system in the future as
a defense against a biohazard.

Since their discovery, liposomes have become popular

drug carriers systems and have been enhanced in order to target specific sites of drug
action such as the brain, cancer, and HIV-infected cells. The liposomes presented in this
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study are loaded with a neutralizing agent MgOCl 2 , capable of reducing Bacillus bacteria
viability.

In order to increase the specificity of these liposomes, their surface was

modified with a polyclonal antibody specific to the spores and vegetative cells of the
bacterium Bacillus cereus (B. cereus) and Bacillus subtilis (B. subtilis). The viability of
the bacterium Bacillus cereus, Bacillus thuringiensis,and Bacillus subtilis was studied in

the presence of the MgOCl 2 liposomes and MgOCl 2 immunoliposomes, compared to the
viability of the bacteria in the presence of free MgOC12.

1.1 Research objectives and specific aims
The primary purpose of this research is to develop a feasible method, capable of
neutralizing Gram positive bacteria such as Bacillus cereus (B. cereus), Bacillus subtilis
(B. subtilis) and Bacillus thuringiensis (B. thuringiensis). Also, it is proposed that the
modified surface of a liposome with a polyclonal antibody against B. cereus and B.
subtilis, has a better neutralization effect than a non targeted liposome.

Due to the

similarities between B. cereus and B. thuringiensisto B. anthracis, it is expected that the
behavior of B. anthracisin contact with the immunoliposomes and with the drug loaded
liposomes will be similar to that of the aforementioned Bacillus species.
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Specific Aims:
1.

Development of surface modified MgOC12-immunoliposomes

with pseudo-

specificity toward B. cereus and B. subtilis bacterium.
2. Determine the efficacy of MgOCl 2-immunoliposomes compared to MgOCl 2
liposomes and free MgOCl 2, against bacterial viability.

1.2 Significance of the Study
The significance of this study stems in the attempt to develop a neutralizing
immunoliposome system for Bacillus bacterium. The neutralizing agent (MgOCl 2 ) that is
able to damage or compromise the membrane cell wall of bacteria was encapsulated
within liposomes and immunoliposomes. The development of this neutralization system
brings

the MgOCl 2 -liposomes

and

immunoliposomes

technology

closer to the

development of a neutralization system capable of detecting and neutralizing the
bacterium in a rapid and effective form. The bactericidal effect observed for the MgOCl 2
immunoliposomes and MgOCl 2 liposomes towards the bacterium B. thuringiensis, B.
subtilis, and B. cereus should be similar towards the bacteria B. anthracis.
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2.0 LITERATURE REVIEW
The Institute of Scientific Medicine affirmed that the United States is not yet
prepared to deal with a bioterrorist attack. There are many bacterial threats that could
risk citizens'

health,

for example Bacillus anthracis, Yersinia pestis, Francisella

tularensis,and Clostridium botulinum (Nolen 2003).

Bacillus anthracis(B. anthracis), the bacteria that causes the disease anthrax, is
the most dangerous bioweapon available to date. The three types of anthrax infections
are cutaneous, gastrointestinal, and inhalation of anthrax.

Cutaneous anthrax occurs

when anthrax spores penetrate a wounded area of the skin; the infection will appear to be
an insect bite. In approximately 2 days, the area will become a fluid filled vesicle, which
will rupture and form an ulcer. As a peculiar characteristic, it will have a black necrotic
area in the center. Approximately 20% of untreated cases of cutaneous anthrax result in
death because the infection becomes systemic (Lenski). Gastrointestinal anthrax may be
caused by consumption of contaminated meat from infected animals and it is
characterized by an acute inflammation of the intestines. Mortality rates are around 2560% (Weyant, Ezzell et al. 2001). Inhalation anthrax is the most lethal type of anthrax.
It is the easiest way of spreading the bacteria in massive amounts. The symptoms of
inhalation anthrax are similar to a common cold. If the patient is not treated within 36
hours he would enter into the lethal phase where chances of survival are not encouraging.
Current methods available to determine the presence of B. anthracistake up to 48
hours (Zayas 2006).

For example, two types of tests performed to detect the presence of

B. anthracis are the phenotypic identification of B. anthracis and antibody based
methods. The phenotypic identification method requires blood cultures and requires 1-2
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days to provide a definitive identification and cultures from skin or lesions (Eduards
2006). Therefore, attention is focused on B. anthracisneutralization in a fast and precise
way, with the purpose of biodefense.

2.1 The Bacillus genus
The family of Bacillus genus distinguishing feature is the production of
endospores formed in the bacteria cell.
bacteria.

Members of this group are Gram positive

Gram positive bacterium cell wall thickness is around 15-18 nm and it is

composed of linear anionic polymers termed teichoic or teichuronic acids that are
covalently linked to the peptidoglycan, giving the membrane cell wall support and
protection (Lambert 2002; Kim, Farrah et al. 2007). The membrane wall is a bilayered
structure and it has a selective permeable barrier that regulates the passage of substances
into and out of the cell. Disorganization of the membrane by undesired or a foreign
substance can cause loss of permeability of the membrane; therefore, causing its death
(Lambert 2002). Liposomes composition is similar to the membrane cell wall and they
can pass easier through it without being recognized as a foreign substance.
All Bacillus strains contain special mechanism of survival which is based in the
production of endospores, the mechanism is activated in reaction to environmental
alterations, such as exhaustion of essential nutrients or stress. The spores are resistant to
extreme environmental changes and when the environmental stress is relieved, they
germinate and become vegetative cells (K. Todar 2005). This mechanism of survival
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makes the elimination of these bacteria even more difficult, and a good bioweapon
resource.
The Bacillus genus contains some toxins, which are generally water soluble and
capable of interacting with the cell membrane. The toxins recognize specific receptors,
which usually are lipids or another molecule that bound to the lipid bilayer. Bacterial
toxins are able to cross lipid membranes, and induce pores to release cell nutrients or kill

target cells by disrupting their membrane.

The pore formation involves dynamic

interactions between hydrophobic protein and hydrophobic lipid bilayers (Geny and

Popoff 2006).
The use of liposomes to carry a bactericidal agent to treat Bacillus bacterium will
provide a faster neutralization effect because they can pass through the membrane cell
wall of the bacteria and the bactericidal toxins permeate the liposomes enhancing the
drug release from the liposomes into the cell.

2.1.1

Bacillus anthracis

Bacillus anthracis (B. anthracis) is the bacteria that cause the disease anthrax. B.
anthracis has a capsule, a proteinaceous

surface layer, and several

layers of

peptidoglycan outside the surface of the plasma membrane. The capsule of B. anthracis
contains poly-D-glutamic acid, which is a major determinant of its virulence.

Of the

Bacillus genus strains B. cereus and B. thuringiensis are the closest relatives to B.
anthracis. Typically B. cereus and B. thuringiensisdo not contain the poly-D-glutamic
acid capsule (Sue, Hoffmaster et al. 2006). B. anthracishas some surface labels, which
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are the major components of the surface layer proteins EA1 and Sap. These labels can be
identified by their specific antibodies anti-EA1 and anti-Sap.

In the presence of the

capsule, there is an absence of immunolabels; therefore, it is suggested that the cell
surface is inaccessible to the EA1 and anti-Sap antibodies.

The presence of the

antibodies could be due to the synthesis of these proteins prior to the complete coverage
of the surface by the capsule or to leakage or bacterial lysis (Mesnage and Tosi-Courture
1998). This suggests that targeting the bacteria with an antibody EA1 or anti-Sap needs
to be done before the bacterium is covered by the capsule. B. anthraciswas not used for
this thesis due to safety precautions, but the Bacillus strains that are described in the
following section were used as a model of these bacteria.

2.1.2

Bacillus thuringiensis

Bacillus thuringiensis (B. thuringiensis) is an anaerobic Gram positive bacterium

that is closely related to B. anthracis and B. cereus. These organisms are capable of
producing endospores and differ mainly in their plasmids (Madigan and Martinko 2005).
This bacterium has been used as the active ingredient of some insecticides because
protein extracts of the bacteria react with the antiprotoxin antibody forming protein
crystals of insecticidal protein toxins. These insecticidal proteins are called Cry proteins;
these proteins have specific activities against Diptera, Cleoptera, and Lepidoptera
species (Du 2005). From previous studies, Bacillus thuringiensis Cry4Ba toxin is shown
to be capable of permeabilizing liposomes and forming ionic channels in receptor free
planar lipid bilayers (Theeraporn Puntheeranurak 2005).
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Figure 1. Bacillus thuringiensis, microscope image, observe the rod shape of the bacteria (K. Todar

2005).

2.1.3

Bacillus cereus

B. cereus is a spore forming bacteria that causes food spoilage and therefore foodborne illnesses (Koo, ForEgeding et al. 1998). This bacterium causes two different types
of food poisoning, which are characterized by either emesis or diarrheal type of
intoxication (Dietrich 1999). The first type of intoxication is the short- incubation period
of 1-6 hours and is characterized by nausea, vomiting, and abdominal cramps.

It

resembles Staphylococcus aureus food poisoning in its symptoms and incubation period.
B. cereus food poisoning occurs year-round and is without any particular geographic
distribution. The short-incubation form is most often associated with fried rice that has
been cooked and then held at warm temperatures for several hours. The second type is
manifested primarily by abdominal cramps and diarrhea with an incubation period of 8 to
16 hours (K. Todar 2005). This bacterium has two different enterotoxin complexes, the
nonhemolytic and hemolysin enterotoxins.

Each of them is composed of three

components with different molecular masses. The components of the hemolysin BL have
been characterized and are required to produce maximum biological activity (Dietrich
1999). The surface protein for B. cereus is used for the production of an antibody from
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immunized animals and it is purified through SDS-PAGE (Hua 2002). B. cereus has an
enzyme called Phospholipase C hydrolyzes with phosphatidylcholine,

the major

component in the liposomes used for this thesis.

2.1.4

Bacillus subtilis

Bacillus subtilis (B. subtilis) is not classified as a human threat, it may
contaminate food but it rarely causes food poisoning. It is commonly found in the soil
and has a protective endospore that protects it from extreme environments. B. subtilis has
become adopted as a model organism; it is used as a Gram positive equivalent of E. coli.

2.2 MgOC12 Nanoparticles as Bactericidal Agent
Nanotechnology is applying science and engineering knowledge for the design
and production of new materials and devices on the nanoscale. Nanotechnology has the
goal of increasing the ratio of the surface area per volume present in many nanoscale
materials. Nanoparticles used as a bactericidal agent are able to cover the bacteria cells
to a high extent bringing the drug's active form, at high concentration, in close proximity
to the cell wall membrane were it acts by damaging the cell wall. This nanomaterial
characteristic was used as the criteria of selection for liposome encapsulation. MgOCl 2
nanoparticles are capable of damaging the bacterial cell wall because they can surround a
higher surface area and create an alkaline environment that destroys the membrane cell
wall of the bacteria (Stoimenov 2002).

Therefore, MgOCl 2 was encapsulated in the

liposomes and tested for bactericidal effect.
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Stoimenov used MgOCl 2 nanoparticles prepared through an aerogel procedure
(AP) to test its bactericidal and sporicidal activity. AP-MgO nanoparticles possess many
properties that are very desirable for a potent disinfectant. AP-MgO nanoparticles have
the ability to absorb and retain for longer periods of time (in the order of months)
significant amounts of chlorine and bromide. It is suggested that AP- MgO nanoparticles
can absorb 20 wt% chlorine. Furthermore, Koper showed that AP-MgO/C

2

formulations

are quite active as biocides, more so than free C12 or AP-MgO itself or commercially
available microcrystalline MgO (Koper, Klabunde et al. 2002). In previous studies by
Stoimenov, it has been proven that AP-MgO/C

2

and AP-MgO/Br 2 changed significantly

the Escherichia coli, Bacillus subtilis, and Bacillus Megaterium cell wall (Stoimenov

2002).

Chlorine action is dependent on pH and temperature.

From the reaction of

chlorine and water, one of the products is HOCi, and pH levels are around 4.0-6.0.
Microorganism killed by disinfectants are assumed to follow the CT concept, defined as
the product of disinfectant concentration and time (Davis and Cornwell 1991).

2.3 Liposomes and Liposome Technology
Liposomes were discovered by A.D Bangham (Segota and Tezak 2006), who was
performing blood clot research on the colloidal behavior of some phospholipids.
Bangham found that phospholipids were capable of forming spheres in diluted aqueous
solutions, and he described the liposomes as the smallest artificial vesicles that can be
produced from natural nontoxic phospholipids and cholesterol (Segota and Tezak 2006).
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Since Bangham's discovery, liposomes are considered as highly versatile structures for
research due to their many applications.
Liposomes can be used to encapsulate and deliver a chemical dissolved in an
aqueous

environment.

Hydrophilic

chemicals

are

entrapped

in the

aqueous

compartments of the liposomes, whereas hydrophobic chemicals are incorporated into
their lipid bilayers (Mugabe, Azghani et al. 2005) (see figure 2). For the purpose of this
research a hydrophilic chemical MgOCl2 was used, and the liposomes entraped it in its
aqueous compartment.
Liposomes have permeability properties similar to biological membranes, also
they are non toxic and non immunogenic. Therefore, interest in these vesicles towards
the study of the interactions between membrane lipids and biomolecule grew due to the
possibility of their use as a model of biological membranes

(Mugabe, Azghani et al.

2005; Eduards 2006; Segota and Tezak 2006). Liposomes can be characterized by size,
number of layers, and surface charge (Segota and Tezak 2006). Liposome size can be
controlled by decreasing the total energy in the dispersed system (Sabin, Prieto et al.
2006).

Liposomes formed with phospholipids have high stability, but have no

thermodynamic stability.

They require some energy input provided by sonication,

electrophoration or extrusion in order to form vesicles.

Initially liposomes consist of

several layers (multilamellar vesicles), which are removed as the extrusion process is
performed to make them unilamellar encapsulating vesicles of a desired size (Segota and
Tezak 2006).

The extrusion procedure was the energy input method used for the

development of the liposomes in this thesis and filter membranes of 100-80 nm were used
in the procedure to make 100nm liposomes.
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Phosphatidylcholine, liposomes are zwitterionic lipids, meaning that they have
zero net charge and that they will repel each other providing colloidal stability to the
phosphatidylcholine liposome system (Malmsten 2002). The membrane of the liposomes
made for this thesis is mainly composed of phosphatidylcholine and Biotin-polyethylene
glycol (PEG) and is "alloyed" with cholesterol (which is the basic constituent of cell
membranes) to improve mechanical stability. This results in a stronger membrane with

reduced permeability (Lasic 1998; Sederatou, Tsiourvas et al. 2000). Cholesterol in
liposomes has been proven to enhance liposomes recognition due to the organization of
the lipids and resulting in a higher lateral motility of the recognizable molecules in the
liquid ordered phase (Sederatou, Tsiourvas et al. 2000).
The stability of the liposomes can be enhanced by the addition of a protective
agent.

In addition, the agent will help avoid aggregation and provide a longer storage

time.

The cryoprotectant trehalose is a non-reducing glucose disaccharide, which is

found in many species of hydrobiotic organism. Trehalose is type of sugar that has been
used to maintain the structural integrity and viability of certain biomaterials, and it was
proven to be capable of maintaining liposome stability in solution for a longer period of
time (Holovati and Acker 2007). Trehalose was used to increase the stability and storage
time of the liposomes created for this thesis.
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Lipid Bilayer

Hydrophilic

Hydrophobic
Area

M9002

Area

l00nm
Figure 2. Liposome structure. Hydrophobic drugs can be entrapped within the liposome lipid
bilayer. MgOC2 is a hydrophilic molecule which was used as a neutralizing agent for the purposes of
this thesis and was entrapped inside the aqueous area of the liposomes.

Liposomes are of great interest to pharmaceutical companies due the drug
encapsulation capacity and the possibility of control of their delivery to a specific target
in the body. Drug targeting by antibody-conjugated liposomes (immunoliposomes), see
figure 3, represents a technology that has been applied to the targeting of specific sites of
drug action, such as the brain, lung, cancer cells or cells of the immune system
(Schnyder, Krahenbuhl et al. 2004). Site-specific targeting depends on the labeling of a
liposome with an antibody and the high affinity between the antibody and its specific
antigen. The use of antibodies in the surface of the liposomes may shorten the detection
and neutralization time from days to hours (Koo, ForEgeding et al. 1998). The efficacy
of the targeting depends on choosing the correct antibody to label the surface of the
liposomes, and the specificity of the antigen against that antibody. The liposomes made
for this application contain Biotin PEG- 2000.
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Biotin is used in many bioanalytical

techniques specifically to form essential irreversible and specific linkages between
biological molecules.

Avidin and the homologous protein Streptavidin are tetrameric

proteins, each can bind up to four molecules of biotin with high affinity (Lo 1999).

Antibody

Figure 3. Surface modification of a liposome with antibodies to increase specificity.

Streptavidin has a high affinity for biotin (Ka ~ 1015 M 1 ) (Wolfgang Frey 1996)
and will form a high strength bond between these two components. Streptavidin provides
four binding sites for the biotin and for an antibody. This will help increase liposome
specificity towards a specific target. The antibody used to demonstrate the specificity of
the liposomes toward the bacterium in this thesis is a polyclonal antibody. Polyclonal
antibodies come from different B cell lines and are a mixture of the immunoglobin
molecules produced by those B cells.

Each immunoglobin differs in the epitope that

recognizes and the strength of the interaction. The recognition of the different epitopes in
polyclonal antibodies may lead to the cross reaction with different species similar to the
target antigen. The antibody to be used in this thesis is the rabbit antibody to Bacillus
spores and is reactive with spores and vegetative cells of Bacillus cereus and Bacillus
subtilis. As indicated by the manufacturer there is a possibility of cross-reaction with
other Bacillus species. As a proof of principle, this polyclonal antibody is sufficient to
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demonstrate the identification of the bacteria by the MgOCl 2-immunoliposomes, but for

later applications, a monoclonal antibody against the target bacteria should be used.

2.4 m-maleimidobenzoyl-N-hydoxysuccinimide

ester (MBS) crosslinker

MBS is a heterobifunctional cross linker that contains N-hydroxysuccinimide
(NHS) ester and maleimide groups that allow covalent conjugation of amine-and
sulfhydryl-containing molecule. NHS esters react with primary amines at pH 7-9 to form
amide bonds, while maleimides react with sulfhydryl groups at pH 6.5-7.5 to form stable
thioether bonds (Pierce Company 2000). MBS was used to add an amine group in the N
terminal of Streptavidin. This amine group will bind to the thiolated antibody used for
this application of anti Bacillus spores.

2.5 2-Iminothoilane (TRAUTS) crosslinker
TRAUTS reagent is a thiolating agent used for the preparation of a disulfide
conjugates (R. 1978). It was used to add a sulfhydryl to the amine group in the anti
Bacillus spores antibody.

The addition of the sulfhydryl group in the antibody will

permit a conjugation with a Streptavidin protein creating a Streptavidin-antibody
conjugate that will bind to the biotin surface of the liposomes created for this thesis.
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2.6 HEPES buffer
HEPES is a zwitterionic buffer, that do not bind Magnesium ions and is usually
used to maintain pH of cell culture media.

It was stored at ambient temperature and

protected from light to avoid the production of hydrogen peroxide ions, and cell toxicity
(Lepe-Zuniga, Jr. et al. 1987; Probes 2001; Incorporation 2006).

2.7 Size exclusion chromatography (SEC)
SEC is use to separate molecules by size. In general, a column is packed with
porous particles of a defined pore size, and the SEC mobile phase is the solvent used to
dissolve the sample for purification. The molecules that are too large to penetrate the
pores elute in the void volume of the column, and high molecular weight molecules elude
first.

Smaller particle have a longer residence time since they interact more with the

column packing and will elude after the larger molecules and therefore the larger
molecules can separate and purified (Mori and Barth 1999).

2.8 Minimum Inhibitory Concentration (MIC) assay
MIC assay is a basic technique used to determine the minimum drug
concentration required to kill a bacterial population in a period of 24 hours. The assay
consists of adding known concentrations of free MgOCl 2 to a certain volume of bacteria
to determine the bactericidal effect compared to the MgOCl2-liposmes.
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2.9 Fluorescent Microscopy
Fluorescent microscopy is used for a rapid identification of bacterial antigens. A
Live/Dead assay kit from Molecular Probes can asses the enzymatic activity of bacterial
cells and is used to quantify the amount of live and dead bacteria in a sample. This kit
provides two dyes, Syto 9 and propidium homodimer.

Propidium homodimer dye

penetrates the compromised membrane of the bacteria. The bacterium stained with this
dye emits a red fluorescent color whereas the intact bacteria membrane will be dyed with
Syto 9 and emit a green fluorescent light. Both can be observed under a fluorescent
microscope with adequate filters (Probes 2004). The green fluorescent emission is due to
the capacity of living cells to cleave the masked nonfluorescent form of green calcein
fluorophore.

The reason for the red fluorescence image in dead cells is the failure to

exclude the ethidium homodimer dye from their nuclei (Ratner, Hoffman et al. 2004).
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3.0 MATERIALS AND LIPOSOMES METHODS

3.1 Materials necessary for the creation of the

liposome

solution

The materials necessary to make the lipid film are 1,2 Disteroyl-sn-Glycerol
Phosphoethanolamine-N- Biotinyl [DSPE-PEG 2000] (from Avanti Polar Lipids) L-aPhosphatidylcholine (Egg-Chicken) (from Avanti Polar Lipids), Cholesterol (Ovine
wool) (from Avanti Polar Lipids) and Chloroform ACS graded (from Fisher Scientific).
The lipid film was hydrated with HEPES Buffer 1M (from Gibco Company) and the
sugar Trehalose was used to preserve the lipids and the bactericidal agent MgOCl 2 (from
Nanomaterials Company).

3.2 Method #1, 100 nm liposome solution preparation
To accomplish the first aim of this thesis, a liposome solution composed of 100
nm sized vesicles was created following Becker's protocol (Becker 2007). This was the
first step leading to the accomplishment of Aim 1.
In order to prepare the lipid solution, 37.5 mg of DSPE- PEG 2000 Biotin (solid),
87.5 mg of L-a-Phosphatidylcholine, and 6.5 mg of cholesterol were weighted and
dispensed into a round bottom flask. In the fume hood, 50 ml of Chloroform were added
and stirred in a round bottom flask for 1 minute to produce a well-mixed solution and to
avoid any particle residue. After mixing, the liposome solution was placed in the rotary
evaporator (rotovap) under low vacuum to assist the evaporation of the chloroform. The
water bath of the rotatory evaporator was set at 40*C, and the water bath of the circulator

was set to 14*C. The evaporation of the solvent was assisted by low vacuum, and the
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rotation was set to 155 rpms. The average time for the solvent to evaporate was one
hour. The lipid film was immersed in liquid Nitrogen three times and it was placed in the
lyophilizer for an overnight procedure.

3.3 Liposome film rehydration
The flask containing the lipid film was rehydrated by an addition of 35mL
HEPES buffer after the overnight lyophilization. The flask was placed in the rotatory
evaporator, and the rotations were set at 100 RPM until the lipid film is completely
dissolved in the HEPES (this process takes approximately 45minutes). After the lipid
film was completely rehydrated, 13.0 mg MgOCl 2 were added to the liposome solution.
The liposome solution containing the MgOCl 2 was placed in the rotatory evaporator at
the same conditions previously mentioned for a period of 15 minutes to help the MgOCl 2
dissolve.

After the drug was dissolved in the liposome solution, the liposomes were

ready for the extrusion procedure (Becker 2007).

3.4 Making 20.0% Trehalose 3mM HEPES solutions

A 3mM HEPES solution was prepared by adding 3 ml of HEPES buffer to a 1000
ml volumetric flask and then filled to the 1000 ml mark with distilled water. The 20.0%
trehalose solution was prepared by adding 20.0 mg of Trehalose to 100 ml of 3mM
HEPES in an Erlenmeyer flask.
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3.5 Extrusion Procedure using the 100 ml extruder
Liposomes

are

not

thermodynamically

stable

therefore

will

not

form

spontaneously (Lasic 1998). Extrusion of the liposomes in a 100 ml extruder provided
the required energy to the system for the formation of the vesicles. The 100ml extruder
needed to be prepared before the extrusion procedure. The extruder parts were cleaned
with water and Alconox anionic detergent and rinsed with 1 M HEPES buffer. After the
instrument parts were cleaned, an extrusion with Triton X was performed followed by ten
HEPES buffer extrusions of 10 ml to remove any liposome residual left in the extruder.
After the extruder was cleaned, the water bath was allowed to heat to 42"C and 15 ml of
the liposomes were added into the extruder tank. The Argon tank and the valve that
allows the flow of the Argon into the extruder (green valve) were opened and the valve
that releases the pressure of the tank was closed and the pressure of the Argon tank was
increased to 100 psi or to the required pressure for the liposomes to start coming out of
the extruder. This process continues until the liposome solution is completely extruded.
The extrusion procedure was repeated 10 times with the 100 nm membrane, the
membrane was replaced every 5 extrusions.

After the tenth extrusion 1 ml of 2%

trehalose was added to the extruded liposomes. Ten extrusions were performed with the
80 nm membrane and the membrane was replaced after 5 extrusions, after the tenth
extrusion 2 ml of 10% of trehalose were added. Finally, 3 extrusions were performed
with a 50 nm membrane and a sample of 1 ml was placed in the Zetasizer Nano ZS (from
Malvern Instruments Ltd.) for size measurement. If the size is in the range of 100-80 nm,
the liposomes are ready for the purification procedure.

Otherwise, 5 more extrusions

need to be performed using a 50 nm membrane, until the liposome size matched the
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desired size range.

This liposome extrusion procedure was established by Michael

Becker 2007 (Becker 2007).

3.6 Liposome Purification
Liposome purification was performed by size exclusion chromatography using a
Sephadex G-50 column. To make the Sephadex-G50 columns, 25 g of Sephadex were
swelled in 250 ml of HEPES (1 Gram swells in 9-11 ml of buffer) at room temperature
for 3 hours or at 90"C for one hour. Glass wool was packed inside a 60 ml syringe. It is
necessary to pre-treat the glass wool for 15 minutes with HEPES buffer before packing it.
The Sephadex-G50 column was placed at low vacuum and 10 ml of liposome solution
was added to the column for purification. The purified liposomes were recovered in a 50
ml Erlenmeyer flask and stored in the refrigerator at 4-8"C. After the purification, the
liposomes size was measured with a Zetasizer Nano ZS manufactured by Malvern
Instruments Ltd.

3.7 Method #2, Streptavidin-Nanoparticle antibody Complex
The development of the Streptavidin- Antibody complex is the second step
leading to the accomplishment of Aim 1.

3.8 Streptavidin Coated Nanoparticle- MBS synthesis
A Streptavidin-MBS complex was developed by mixing 40 pl of Streptavidin in
5 ml of a 16.0 mM HEPES solution (4.3 ml of dionized water, and 0.7 mL HEPES) in a
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15 ml flask. A 40:1 molar excess of MBS solution was added to the diluted Streptavidin
by adding 200 pl of MBS solution.

3.8.1

MBS 40:1 Molar Excess

Following the instructions from the Pierce company protocol; 3.14 mg of MBS
was dissolved in 1 mL of DMSO to make a 10 mM MBS solution. The preparation of
the molar excess consists of adding 40

l of Streptavidin to the MBS solution. A 40:1

molar excess of MBS solution is prepared by adding 200pl of MBS to 40 pl of
Streptavidin solution.

The MBS-Streptavidin Complex was purified following the

standard protocol of a 30 Centriprep Ultrafiltration Device from Millipore.

3.9 Antibody Thiolation
The antibody needs to be thiolated before it can bind to the available maleimide
in the Streptavidin-MBS complex.

A 40:1 molar excess of TRAUTS powder, was

prepared by dissolving 1 mg of TRAUTS in 200pl of HEPES. The antibody (rabbit
antiBacillus spores) (40p1) was diluted in 2 ml of HEPES 1M. A 40:1 molar excess was
added to the diluted antibody with the buffer flask, and it was placed in a gently stirred
water bath at room temperature for one hour. After the antibody thiolation, purification
by size exclusion chromatography was performed in a Sephadex 25-G column.
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3.10

Method #3, Conjugation of the Streptavidin- Antibody Complex

The third and final step for the accomplishment of Aim 1 consists of the
formation of the Streptavidin-MBS complex and the conjugation of the complex with the
liposomes.
In order to obtain the Streptavidin-Antibody complex, 150 pl of the StreptavidinMBS Complex were mixed with 500 pl of the antibody-TRAUTs into a 15 ml conical
tube and vortexed it for 20 seconds. This complex was left in a water bath overnight to
permit the conjugation to take place.
The MgOCl2-immunoliposomes were made with a 1:1 ratio of the MgOCl 2
liposomes and the Streptavidin-Antibody complex.

The MgOCl2-immunoliposomes

inside the 15 ml flask were placed in a water bath at room temperature, and stirred for 30
minutes to ensure the reaction took place.

Figure 4. Schematic of the biotinylated liposome surface, modified with the Streptavidin- An 'body
Complex, where <0 represents Streptavidin, frepresents the anti-Bacillus spores antibody, [ and
represents the PEG-2000 Biotin.
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3.11

BCA Assay

To determine the concentration of proteins (antibody) in the Streptavidin-

antibody complex, a BCA assay was performed.

This assay is required for the

quantification of the total protein attached to the surface of the liposome (Streptavidin
and the anti Bacillus spores antibody).
The BCA assay is based on the reduction of Cu+2 to Cuel by proteins.

The

reduction is proportional to the protein present in a solution. The biuret product that is in
contact with the Cu' turns violet is an indicator of protein presence (Pierce Company
2006). The assay comes with to reagents that mixed together in a 50:1, A to B. This
mixture is called the working solution. This solution makes the samples change from
clear to color purple when protein is present. The manufacturer standard protocol is
followed to create the standard solutions in order to obtain the absorbance values in the
spectrophotometer. The obtained data was used to determine the protein concentration.
The absorbance of the standard and the Streptavidin-Antibody sample was determined in
a TECAN spectrophotometer at 595 nm.

A standard curve of absorbance vs.

concentration was created in Microsoft Excel. With the standard curve, the values of the
absorbance obtained for the Streptavidin-Antibody complex were used to find the total
protein concentration in this complex.

3.12

Method #4, Bacteria Preparation

In order to test the MgOCl2-immunoliposomes to accomplish Aim 2 a standard
protocol of bacteria preparation was followed as described in the next section.
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3.12.1 Luria Broth Media Preparation
Fresh Luria Broth bacteria media was made by adding 20 g of Luria Broth (LB) to
1000 ml of distilled water into 2000 ml Erlenmeyer flask. This solution was stirred in a
stirring plate at high velocity until a homogeneous solution was observed.

After the

solution was prepared, it was placed into the autoclave equipment for a period of 50
minutes in the liquid cycle.

3.12.2 Agar Preparation
As recommended in the standard protocol for agar preparation, 40 mg of agar
powder was added to 1000 ml of dionized water. The solution was well mixed with a
magnetic stirrer for 15 minutes. The agar solution was placed in the autoclave for 25
minutes.

After removing from the autoclave, the solution was placed in the magnetic

stirrer mixer to cool down the solution. After the solution is warm enough, it was poured
in the agar plates.

3.12.3 Bacteria Culture
Basic bacteria culture procedures like bacteria streaking and bacteria inoculation
was followed. Bacteria stocks were placed in a -80"C freezer; the vials were taken from
the freezer; and was warmed in the hands. With a pipette tip, obtain some cells from the
freeze stock and streak in the agar plate as shown in figure 5.

25

Figure 5. Plate streaking sample. The number 1 indicates the streaking starting point

After streaking the desired number of culture dishes, the plates were placed inside
an incubator at physiological conditions (37"C) overnight.

3.12.4 Bacteria Inoculation
Sixteen hours after the streaking incubation, the culture dishes were removed
from the incubator and placed in the bench top until a selection of one isolated colony
was made. The selected colony was scraped with a round tip and then mixed in a 50ml
Erlenmeyer flask with 10 ml of Luria Broth. The bacterial solution was placed inside a
shaking incubator at 37*C overnight. A bacteria concentration was determined using an
Optical Density Spectrophotometer analysis at 600 nm. From this concentration, 4 serial
dilutions of 1:10 were made to reach theoretical concentration of 1xi 05 cells/ml.

3.13

Protocol 1, BCA assay

The most important step to develop a successful BCA assay to obtain the
unknown amount of protein in solution, is to generate a standard curve of Absorbance vs.

26

Concentration. The standard solutions were prepared following the instructions provided

by the manufacturer in Table 1.

Three samples of twenty five microliters each of the

standard dilutions were pipetted into a 96-well microplate with 200

l of working

reagent. The plate was then shaken for 30 seconds and incubated at 60"C for 30 minutes.
After 30 minutes of incubation the microplate was cooled at room temperature for 30
minutes. The absorbance reading was measured in the Tecan instrument at 595 nm. An
Absorbance vs. Concentration curve was performed with the averages of the measured
absorbance values subtracted to the blank standard measurement at 595nm.

Vial

Volume of Diluent

Volume and Source of BSA

Final BSA concentration

A

720 l

80 l of stock

200 g/ml

B

300 pd

500 l of vial A dilution

125 pg/ml

C

160 l

640 l of vial B dilution

100 g/ml

D

400 pl

400 pl of vial C dilution

50 pg/ml

E
F

400 l
800 l

400 l of vial D dilution
0

25 pg/ml
0 pg/ml= Blank

Table 3-1. Dilutions for enhanced BCA standard. Preparation of diluted albumin (BSA) standards
dilution scheme for enhanced protocol microplate (working range 200-5 pg/ml) modified from
Thermo Scientific Pierce Protein Research Products, protocol.

3.14

Protocol 2, Minimum Inhibitory Concentration Test

In order to determine the MgOCl 2 liposomes effectiveness compared to the free
drug at different concentration effectiveness, a Minimum Inhibitory Concentration assay
was performed.

MgOCl 2 was diluted with 1M HEPES buffer to create solutions at

concentrations of 2M, 1M, 0.5M, 30mM, 3mM, 1.5mM, 0.75mM, 0.3mM, 0.15mM, and
0.075mM.
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B. thuringiensis cultured overnight was diluted 5 times to a theoretical cell

concentration of 1x105 cells/ ml. Optical density measurements at 600nm were recorded.
One hundred and fifty microliters of the diluted bacteria was placed inside a 96-well plate
and mixed with 150 gl of the different MgOCl 2 solutions.

At time 0, 100 pl of the

bacterial solutions were plated in a Petri Dish. The 96-well plate was placed inside a
shaking incubator at physological conditions for a period of 22 hours. After 22 hours
100pl of the 96-well plate were plated in a Petri Dish and incubated at physiological
conditions for 8 hours to observe the bacterial growth.

The 96-well plate and Petri dishes were filled and identified as described in Table 2.
Plate Identification
A
B.
C.
D
E
F
G
H
A6
B6
C6
D6

Contents
HEPES + B. thuringiensis
2M MgOCl 2 + B. thuringiensis
1 M MgOCl 2 + B. thuringiensis
0.5M MgOCl 2+ B. thuringiensis
30mM MgOCl 2 + B. thuringiensis
3mM MgOCl 2 + B. thuringiensis
1.5mM MgOCl 2+B. thuringiensis
0.75mM MgOCl 2 +B. thuringiensis
0.3mM MgOCl 2+B. thuringiensis
0.15mM MgOCl 2 + B. thuringiensis
0.075mM MgOCl 2 + B. thuringiensis
MgOCl 2 liposomes + B. thuringiensis

Table 3-2. 96-well plate and Petri dish contents for the minimum growth concentration assay.

3.15

Protocol 3, Colony Growth inhibition assay (CGA)

This assay was used to accomplish aim 2 to quantify the effect of the MgOCl 2immunoliposomes and MgOCl 2 liposomes towards B. thuringiensis.
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Bacillus thuringiensis was streaked and inoculated using standard protocol

described above. A 100 pl sample of each bacterium strain was taken from the flask
inoculated overnight, and diluted with 900 pl of Luria Bertani (LB) broth. Five hundred
micro liters of the diluted sample were placed in a 1 cm 3 cuvette. An optical density
analysis was taken at 600 nm wavelength to determine the original bacteria
concentrations. Four serial dilutions of 1:10 were performed. The diluted bacteria were
divided in four 15 ml flasks.

Flask number four was filled with 2 ml of the fourth

dilution (containing 2.5 ml of third dilution plus 22.5 ml of Luria Broth). A quantity of
1.5 ml of HEPES buffer was added to 15 ml flask number one, the same amount of empty
liposomes, MgOCl 2 liposomes, and MgOCl2-immunoliposomes were added to flask
number 2, 3, and four respectively.

The same solutions prepared for B. cereus were

prepared for the bacteria B. thuringiensis and B. subtilis. Two 1:10 serial dilutions were
performed in order to obtain less than 300 colonies in the plates. The control plates of B.
cereus and B. thuringiensis contain l00pl of each of the flasks prepared in four different
Petri dishes at time zero. After one hour of incubation, 100pl of each flask was plated in
four different Petri dishes. After three hours of incubation, 100pl of each of the solutions
was plated onto four different plates.

The same procedure was repeated for B.

thuringiensis, but only with the difference of control plate containing 100pl of each
solution. All the plates were incubated overnight at 37"C.
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1.

Bacteria Streaking, incubation
overnight at physiological conditions

2. Isolated Colony Inoculation
at physiological conditions

3. Serial Dilutions with

LB Buffer

4. Addition of a 1:1
( Bacterial sol: liposomes sol.),
Plating and Incubation.

10

ml

10 ml

10 ml

Figure 6. Colony growth assay (CGA) summary procedure. 1. Bacteria Streaking schematic, 2. One
isolated colony from the streaked plate is inoculated overnight in LB broth at physiological
conditions. 3. Five serials dilutions were performed in order to have approximately 1x104 cells/ ml ,
a 1:1 ratio (Bacterial solution: HEPES, Empty liposomes, MgOC 2 liposomes, MgOC 2
immunoliposomes and 3mM MgOCl 2 in five different vials). 4. At time 0 hours 100 l of the solutions
prepared in step 3 were plated in petri dishes, the solutions were incubated at physiological
conditions for two hours and plating were performed for each hour. In a period of 6-8 hours the
colonies become visible and the CFU count was performed.

3.16

Protocol 4, Fluorescent Microscopy

To identify the effect in the membrane cell wall of the bacteria caused by the
MgOCl 2 liposomes and the MgOCl 2 immunoliposomes a live/dead assay for cell viability
was performed.

The bacteria samples in contact with the MgOCl 2 liposomes and the

MgOCl2-immunoliposomes were dyed with the backlight kit L7012 from Molecular
Probes that contain propidium iodide and Syto-9. If the membrane cell wall is damaged,
propidium iodide will enter inside the cell and bind to nucleic acid. This will produce the
red image as an indication of dead or damaged cell. In contrast, Syto-9 will make a green
fluorescent image as a result of the labeling of the dyed nucleic acids in the bacteria
without damage in the membrane cell wall. The protocol followed was as provided by
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the company. The bacteria was grown overnight.

From the bacteria culture, 30 ml of

bacteria were grown until an absorbance of 1 AU was observed. After this absorbance
was obtained, 25 ml were centrifuged for 15 minutes at 9000g in Sorval RT 6000 Series
Centrifuge. The supernatant was decanted and the pellet was resuspended in 2 ml of
0.85% of NaCl (saline solution). The 2 ml of bacterial suspension was divided into two
vials. One vial contained 20 ml of Isopropyl Alcohol and the second vial contained 20
ml of 0.85% of saline solution. The vials were incubated for one hour and mixed every
15 minutes. The cells were centrifuged at 9000g for 15 minutes. The supernatant was
decanted from both vials and the pellet was re-suspended in 20 ml of the 0.85 % saline
solution.

The centrifugation procedure was repeated for the last time at the same
The supernatant was decanted and the pellet was re-

conditions previously mentioned.

suspended. The bacterial concentration was adjusted to 1 x108 cells/ml and it was stained
with a mixture of the propiduim iodine and Styo 9.

It was then observed under the

fluorescent microscope.

B.

suubiiis

Figure 7. Schematic representation of MgOClr1immunoliposomes attached to the antigens
subtilis
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4.0 RESULTS

4.1 Liposome Size
Liposome size measurements were performed in the Malvern Zeta Sizer.

The

liposome size varied between 50 nm and 500nm with averages size of 100-149 nm
(Figures 8-17). The liposomes were kept at 4*C and weekly size distribution test readings
were performed in the Malvern Zetasizer to determine the stability of the liposomes in
solution. The polydispersity index of the empty liposome solution doubled after a week
but remained stable for a period of three weeks. The polydispersity index for MgOCl 2
liposomes remained stable for three weeks. In the third week of storage the MgOCl 2
liposomes size increased suggesting liposome swelling or aggregation. On the third week
empty liposomes size and polydispersity also increased.
MgOCl 2 liposomes and empty liposomes at 4 weeks of storage at 4"C, showed a
polydispersity index (PdI) of above 0.2, and more than one peak in the size distribution
curve.

The MgOCl 2 liposomes with the antibody attached to its surface showed a

polydispersity index of above 0.2 and a second peak on the size distribution curve after
one week of storage at 4*C.
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Figure 8. Empty liposomes size distribution curve on the 1st day of storage at 4"C. Obtained in the
Malvern Zetasizer for liposomes after extrusion and trehalose addition. The polydispersity index
corresponding to this curve is 0.059 and the average Z size is 123 nm.
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addition of trehalose. The polydispersity index corresponding to this curve is 0.093 and the average

Z size is 108nm.
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Figure 13. MgOC12 liposomes, stored at 4"C for 3 weeks. The polydispersity index corresponding to
this curve is 0.122 and the average Z size is 146 nm.
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Figure 15. Empty liposomes batch 2, stored at 4"C 4 weeks. Size Distribution curve obtained in the
Malvern Zetasizer for liposomes after storage in 4"C for a 4 weeks period. The polydispersity index
corresponding to this curve is 0.283 and the average Z size is 50.8 nm.
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Size Dstribution by Intensity
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Record 7: purified f'Q lip

Figure 16. MgOC12 liposomes batch 2, on the 1st day of storage at 4"C. Size Distribution curve
obtained in the Malvern Zetasizer for liposomes after extrusion and Trehalose addition, on the 1st
day of storage. The polydispersity index corresponding to this curve is 0.299 and the average Z size

is 125 nm.
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Record 8:

tO2

Liposome 17 dec check on January 1

Figure 17. MgOCl 2 liposomes batch 2 stored at 4C 4 weeks. Size Distribution curve obtained in the
Malvern Zetasizer for liposomes after 4 weeks of storage. The polydispersity index corresponding to
this curve is 0.653 and the average Z size is 61.4 nm.

37

Size Distribution by Intensity
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Record 29: Inmnoliposomes shelf life check made on Jan 15 2008

Figure 18. MgOC 2 immunoliposomes 1s day of storage at 4"C. Size Distribution curve obtained in
the Malvern Zetasizer for liposomes where the polydispersity index corresponding to this curve is
0.299 and the average Z size is 120 nm.
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Record 20: immunoliposomes made on Jan 15 shelf life check

Figure 19. MgOC12 immunoliposomes stored 10 days at 4*C. Size Distribution curve obtained in the
Malvern Zetasizer for liposomes after 10 days of storage. The polydispersity index corresponding to
this curve is 0.235 and the average Z size is 103nm.
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4.2 BCA Assay
The BCA assay standard curve was used to approximate the amount of total protein

(Streptavidin plus Anti-Bacillus antibody) present after the crosslinking and purification
of the Streptavidn-Antibody complex. The average absorbance for the protein solutions
after subtracting the average 595 nm absorbance measurement of the blank standard was
0.048. From this value an interpolation in the BCA standard curve was done to obtain a
44.2 pg/ml concentration for the Streptavidin-Antibody complex.

y = 0.0012x - 0.0048
R2 = 0.9939

BCA Standard Curve
0.160.140.120.1
0.08-

0.060.040.02 0
-0.02

20

40

60

100

80

120

140

Concentration (ug/ml)
*

BCA standard curve

A Streptavidin-Ab complex

-

Linear (BCA standard

cure)

Figure 20. BCA standard curve. The Streptavidin-antibody absorbance and concentration point is
represented with the black triangle (44.2 pg/ml, 0.0482).
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4.3 Minimum Inhibitory Concentration (MIC) assay
B. thuringiensiswith a theoretical concentration of 1x105 cells/ ml was incubated

for a period of 22 hours with different MgOCl 2 solution concentrations 2 M; 1 M; 0.5 M;
30 mM; 3 mM; 1.5 mM; 0.75 mM; 0.3 mM; 0.15 mM; 0.075 mM; and MgOCl 2
liposomes. Samples of 100 pl were plated in different Petri dishes at time 0 and after 22
hours of incubation, the bacterial growth was observed.

The plates containing high

MgOCl 2 concentrations (2 M, 1 M and 0.5 M) showed no bacterial growth. Bacterial
growth was observed in the plates that contained the drug concentrations from 30 mM to
0.075mM plates A6, B6, C6, A, F, E, G, and H (Figure 19). The plate containing the
MgOCl 2 liposomes incubated with the bacteria (D6) had no bacterial growth, indicative
of the efficiency provided by the liposomes.

A6

B6

A

F

C6

D6

B

C

D

E

G

H

Figure 21. MIC for B. thuringiensis after 22 hours of incubation. Observe plates A6, B6, C6, A, F, E,
E, G, H bacterial growth. In plates B, C, D, and D6 you can see through the plate, and no bacterial
growth was observed. See table 2 for plate identification.

4.4 Colony Growth Assay (CGA)

A CGA for B. thuringiensis was performed as a quantification method for the
bactericidal effect of the MgOCl 2 liposomes, and the MgOCl 2 immunoliposomes. A two
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sample paired t-test for means was used to compare the reduction effect caused by

HEPES buffer; empty liposomes; and 3mM MgOCl 2 to the MgOC

2

liposomes and

MgOCl2-immunoliposomes effect.

Test 1

Test 2

Test 3

Test 4

Avg

Stdev

1 hour
2 hours
Empty liposomes

0.0
0.0

0.0
0.0

0.0
0.0

0.0
0.0

0.0
0.0

0.0
0.0

1 hour
2 hours

36.2
100.0

30.3
0.0

78.0
0.0

31.9
100.0

44.1*
50.0

22.7
57.7

57.8
26.5

55.1
60.3

80.0
40.0

38.0
33.8

57.7 *+
40.2 *

17.2
14.5

0.0
0.0

20.8
57.7

52.3
38.3

0.0
0.0

18.3
24.0

24.7
28.8

HEPES

MgOC

2

liposomes

1 hour
2 hours
MgOCl2
immunoiposomes

1 hour
2 hours
3mM MgOCI2

1 hour

0.0

0.0

32.0

0.0

8.0+

16.0

2 hours

0.0

41.7

34.8

0.0

19.1

22.3

Table 4-1. Reduction percentages of four different tests for B. thuringiensis CGA, where * means p
value < than 0.05 compared to Hepes and + means p value < 0.05 compared to empty liposomes.
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4

(A)

(B)

Figure 22. Colony growth assay (CGA) for test #1 (A) CGA for B. thuringiensis after 1 hour (B)
CGA for B. thuringiensisafter 2 hours of treatment with MgOCl 2 solutions, incubated overnight.
Where 1, is B. thuringiensis in HEPES, 2, is B. thuringiensis in Empty liposomes, 3, B. thuringiensis

in MgOC12 immunoliposomes, 4, is B. thuringiensis in MgOCl 2 liposomes, and 5, is B. thuringiensis in
3mM MgOC 2 solution.

CGA p values from the t:Test after 1 hour of treatment with bacteria

HEPES
Empty liposomes
MgOCl 2 lip
Immunoliposomes
3mM MgOCl 2

B. thuringiensis

B. thuringiensis

P value compared to HEPES
buffer
N/A
0.015
0.034
0.12
0.20

P value compared to Empty
liposomes
0.015
N/A
0.47
0.010
0.00099

Table 4-2. B. thuringiensis CGA P values from a t-Test comparing the effect of MgOC

3mM MgOCl2 and MgOCJ2-immunoliposomes vs. the control HEPES and empty
of bacteria treatment.
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2

liposomes,

liposomes at 1 hour

CGA p values from the t:Test after 2 hours of treatment with bacteria
B. thuringiensis

B. thuringiensis

HEPES
Empty liposomes

P value compared to HEPES
buffer
N/A
0.090

P value compared to Empty
liposomes
0.090
N/A

MgOCl 2 lip

0.0057

0.40

Immunoliposomes

0.097

0.29

3mM MgOCl 2

0.092

0.25

Table 4-3. B. thuringiensis colony growth assay (CGA) P values from a t-Test comparing the effect

of MgOCl2 liposomes, 3mM MgOCl 2 and MgOCl 2-immunoliposomes vs. the controls HEPES and
empty

liposomes

at 2 hours of bacteria treatment.

CGA p values from the t:Test, comparison of the general effect of liposomes vs. the
controls
B. thuringiensis

B. thuringiensis

HEPES
Empty liposomes

P value compared to HEPES
buffer
N/A
0.00687

P value compared to Empty
liposomes
0.0272
N/A

MgOCl 2 lip

4.87E-05

0.0178

Immunoliposomes

0.0242

0.457

3mM MgOCl 2

0.0410

0.253

Table 4-4. B. thuringiensis colony growth assay (CGA) P values from a t-Test comparing the general

effect (combining 1 and 2 hours) of MgOCl 2 liposomes, 3mM MgOCl 2 and MgOCl2immunoliposomes vs. the controls HEPES and empty liposomes.

4.5 Live/Dead Assay
The bacterium B. thuringiensis, B. subtilis and B. cereus were incubated with 5
different solutions; HEPES buffer; empty liposomes; MgOCl 2 liposomes; MgOCl 2
immunoliposomes; and 3mM MgOCl 2 . The vials containing the different solutions were
centrifuged in a Pico Fuge microcentrifuge at 10,000 RPM for 10 minutes.

The

supernatant was removed and 1 ml of HEPES, Empty liposomes, MgOCl 2 liposomes,
MgOCl2 immunoliposomes, or 3mM MgOCl 2 solutions were re-suspended in each vial.
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Three (3) samples of 150 p of the re-suspended solution were placed in a 96-well plate

and 0.15 pl of the mixed fluorescent dyes was added to the solutions. The 96-well plate
was incubated for 15 minutes. Three microscope slides were prepared with 5 pl of the

dyed solution and observed at 40X under the fluorescent microscope. A total count of
100 live and dead cells was performed and pictures were captured.

Reduction

percentages at time 0 hours and 1 hour are shown on tables 7, 8, 10, 11, 13, and 14. In
order to determine the statistical significance of the reduction percentages obtained, a two
sample paired t-test for means was performed The t:test compared the reduction
percentages of the bacteria incubated with the controls, HEPES, and empty liposomes, at
time 1 hour versus the reduction effect of the liposomes and free drug at 1 hour of
incubation.

The tables presenting the p-values for B. thuringiensis, B. cereus and B.

subtilis are 9, 12, and 15 respectively.

4.5.1

Bacillus thuringiensis live/dead assay results

Average reduction times of B. thuringiensis at 0 hour of incubation with the solutions

Test 1
Test 2
Test 3
Avg
Stdev

liposomes

Avg. Reduction
% MgOCl 2
immunoliposomes

Avg.
Reduction
% 3mM
MgOCl 2

15.0
37.0
12.5
21.5
13.5

15.0
26.0
18.9
20.0
5.6

7.7
11.3
19.5
12.8
6.0

Avg.
Reduction
% HEPES

Avg.
Reduction
% Empty
Liposomes

Avg.
Reduction
% MgOCl 2

12.3
14.0
28.0
18.1
8.6

4.3
20.7
19.0
14.7
9.0

Table 4-5. B. thuringiensis, live/dead assay reduction percentages averages at time 0 hr. At this time
non significant reduction percentages were observed in the t:test performed.
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Average reduction times of B. thuringiensisat 1 hour of incubation with the solutions

Avg.
Reduction
% HEPES
Test 1

8.7

Avg.
Reduction
% Empty
liposomes
7.7

Avg.
Reduction
% MgOCl 2
liposomes
20.0

Avg. Reduction
% MgOCl 2
immuno-

Avg.
Reduction
% 3mM

liposomes

MgOCl 2

22.0

13.0

Test 2

10.7

18.7

32.0

27.0

30.0

Test 3

25.3

31.1

43.0

40.0

36.0

Avg
Stdev

14.9
9.1

19.2
11.7

31.7**
11.5

29.7*+
9.3

26.3+
11.9

Table 4-6. B. thuringiensis, live/dead assay average bacterial reduction percentages at time 1 hr,
where * means p value < than 0.05 compared to HEPES and + means p value < 0.05 compared to

Empty liposomes

B. thuringiensis live/dead assay p values from the t:Test samples for means at time 1
hour

HEPES
Empty liposomes
MgOCl 2 liposomes
MgOCl 2 -Immunoliposomes
3 mM MgOCl 2

B. thuringiensis
P value compared to
HEPES buffer
N/A
0.128
0.0145
0.0071
0.0560

B. thuringiensis
P value compared to
Empty liposomes
0.128
N/A
0.000554
0.0157
0.0371

Table 4-7. B. thuringiensis, P values from a t-test: for means. The reduction percentage caused by
the controls (HEPES and empty liposomes) were compared to the effect of the MgOCl2 liposomes,
MgOC12-immunoliposomes and 3mM MgOCl 2 after one hour of incubation.

Significant reduction percentages were observed for the MgOCl 2 liposomes;
MgOCl 2 -immunoliposomes, and 3mM MgOCl 2 . The highest reduction percentage was
observed in the MgOCl 2 liposomes 31.7%, compared to a 26.0% reduction caused by the
free drug and a reduction of 29.0% was observed for the MgOCl 2-immunoliposomes.
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4.5.2

Bacillus cereus, live/dead assay results

Average reduction times of B. cereus at 0 hours of incubation with the solutions

Avg.
Reduction
% HEPES

Avg.
Reduction
% Empty

Avg.
Reduction
% MgOC 2

Avg. Reduction
% MgOCl 2
immuno-

Liposomes

liposomes

liposomes

Test 1

14.14

14.7

13.0

10.0

Test 2

30.56

10.9

20.5

13.0

Test 3

26.0

10.6

20.2

21.6

Avg
Stdev

23.6
8.5

12.1
2.3

17.9
4.2

17.3
6.0

Table 4-8. B cereus, percentage reduction averages using different solutions at time 0 hr for the live
dead assay.

Average reduction times of B. cereus at 1 hour of incubation with the solutions
Avg.
Reduction %
HEPES

Avg.
Reduction %
Empty
Liposomes

Avg.
Reduction %
MgOC 2
liposomes

Avg. Reduction %
MgOC12 immunoliposomes

Test 1

32.2

26.0

34.6

38.0

Test 2

28.5

34.0

27.7

32.7

Test 3

31.0

32.0

29.0

20.0

Avg
Stdev

30.5
1.9

30.7
4.2

30.4
3.7

30.2
9.3

Table 4-9. B cereus, percentage reduction averages using different solutions at time 1 hr for the live
dead assay.
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B. cereus live dead p values from the t:Test paired two samples for means

HEPES
Empty liposomes
MgOC 2 liposomes
MgOCl2-Immunoliposomes

B. cereus

B. cereus

P value compared to
HEPES buffer
N/A
0.487
0.471
0.480

P value compared to
Empty liposomes
0.487
N/A
0.482
0.479

Table 4-10. B. cereus, P values from a t-test: for means, comparing the significance of the effect on
the 2 controls HEPES and Empty liposomes vs. the MgOCl2 ilposomes and MgOC12
immunoliposomes. The reduction percentage caused by the controls HEPES and empty liposomes at
time 1 hr was compared with its reduction percentage after 1 hour of incubation to the effect of the

MgOCl2 liposomes and MgOC12-immunoliposomes one hour of incubation.

The reduction percentage of B. cereus at time 1 hour in solution with HEPES

buffer was compared with the effect of the bacteria in solution with empty liposomes,
MgOCl 2- liposomes, and MgOCl2-immunoliposomes. The statistical analysis revealed a
non-significant increase in reduction percentage.

The same statistical analysis was

performed for the comparison of the effect of empty liposomes at time 1 hour with the
aforementioned solutions.

The statistical analysis result of this assay revealed a non

significant bactericidal effect on B. cereus caused by the MgOCl 2 liposomes and
MgOCl 2-immunoliposomes. The result for this experiment showed a similar reduction
percentages averages (30.5, 30.7, 30.4, and 30.2) for each solution.

The reduction

percentage observed in the controls can be due to the presence of hydrogen peroxide in
the HEPES buffer.
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4.5.3

Bacillus subtilis

live/dead

assay results

Average reduction times of B. subtilis at 0 hours of incubation with the solutions

Avg.

Avg.

Avg.

Avg. Reduction %

Reduction %

Reduction %

Reduction %

MgOC12 immuno-

HEPES

MgOCl2
liposomes
16.0

liposomes

Test 1

10.0

Empty
Liposomes
11.9

Test 2

24.0

13.6

7.0

6.0

Test 3

27.0

16.0

21.0

35.9

Avg
Stdev

20.3
9.1

13.8
2.1

14.7
7.1

16.0
17.3

6.0

Table 4-11. Bacillus subtilis average reduction bacterial percentage at time 0 hr.

Average reduction times of B. subtilis at 1 hour of incubation with the solutions
Avg.
Reduction %
HEPES

Avg.
Reduction %
Empty

Avg.
Reduction %
MgOCl 2

Liposomes

liposomes

Avg. Reduction %
MgOCl 2 immunoliposomes

Test 1

20.0

28.9

38.0

37.5

Test 2

23.0

18.0

45.7

25.0

Test 3

26.0

23.0

53.0

40.8

Avg

23.0

23.3

45.6*+

34.4+

Stdev

3.0

5.5

7.5

8.3

Table 4-12. Bacillus subtilis average reduction bacterial percentage after 1 hr of incubation with the
different solutions, where * means p value < than 0.05 compared to Hepes and + means p value <
0.05 compared to Empty liposomes

The reduction percentages observed at time 0 hours suggests that the HEPES
buffer caused the highest reduction percentages, but after the bacteria was incubated for
an hour the effect of HEPES on the bacteria remained stable while the effect of the
MgOCl2 liposomes and MgOCl 2 immunoliposomes significantly increased.
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This

suggests that the reduction effect observed at time 0 hours for HEPES is not persistent

and will disappear after time.

B. subtilis live dead p values from the t:Test for 1 hour of incubation with bacteria
B. subtilis

B. subtilis

HEPES Buffer
Empty liposomes

P value compared
HEPES buffer
N/A
0.476

MgOCl 2 liposomes

0.00650

0.0390

MgOCl 2-Immunoliposomes

0.0670

0.0400

to

P value compared to
Empty liposomes
0.476
N/A

Table 4-13. B. subtilis, P values from a t-test: for means, comparing the significance of the effect on

the

2 controls

HEPES and empty liposomes

vs.

the MgOCl 2 iposomes

and MgOC12

immunoliposomes. The reduction percentage caused by the controls HEPES and empty liposomes at
time 1 hr was compared with its reduction percentage after 1 hour of incubation with the effect of the
MgOCl 2 1iposomes, MgOCl 2-immunoliposomes after 1 hour of incubation.

Reduction percentages of Bacillus subtilis at time 0 hours and 1 hour of
incubation are presented in table 11 and 12, respectively.

The bacterium B. subtilis

incubated one hour with empty liposomes and HEPES buffer did not showed a significant
reduction percentage.

The bacteria show a significant increase in the reduction

percentage of MgOC12 liposomes compared to both controls.

The immunoliposomes

reduction was 34.4%. The immunoliposomes showed a significant reduction percentage
when it was compared to the empty liposomes reduction percentage.
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5.0 DISCUSSION
The MgOCl 2-liposomes and empty liposomes developed for this thesis preserved its

size stability for a period of 15 days, stored at 4*C. In figure 8, the empty liposomes size
distribution curve varied between 80nm and 500nm with an average size distribution of

123nm, the polydispersity index (PdI) of 0.059 approximate 0.06 is considered to be a
monodispersed solution. This result coincides with Lieberman et al. in their 1998 book,
where they state that polymer dispersions with a PdI between 0.03 and 0.06 are
considered to be monodispersed solutions.

The polydispersity index (PdI) doubled

(figure 9) showing some instability after one week of storage and remained stable after 10
more days of storage (figure 10).
In figure 11, the MgOCl 2 liposomes size distribution curve varied between 50-500nm
with an average size of 108nm. The polydispersity index of 0.093 approximately 0.1, is
in the range of 0.1-0.2 which is generally found in colloidal drug carriers (Lieberman,
Rieger et al. 1998), suggesting that MgOCl2 drug was encapsulated within the liposomes.
MgOCl 2 liposomes showed more stability than empty liposomes in storage for one week
(figure 12) the PdI average size distribution remained stable, on the third week of storage
MgOCl 2 liposomes PdI increased also the average size (figure 13) suggesting the starting
of liposome degradation.
The size distribution curve of the empty liposomes and MgOCl 2 liposomes showed
more than one peak with PdI of 0.283 and 0.653 after 4 weeks of storage at 4"C
respectively. The formation of new peaks of large size (800nm) observed in figure 15
suggests that some liposomes were coalescing. In addition, the shift in the peak of the
empty liposomes average size distribution curve to the left suggests that many small lipid
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particles (in the range of 20-100nm) related to the degradation of the liposomes were in

the solution, causing a shift in the size distribution curve to the left.

The high

polydispersity index (above 0.2) observed in the size distribution curve for the empty
liposomes size distribution curve also indicated a broad size distribution, as the particle
size range varied from 20-1000 nm (figure15).
In figure 17, the formation of a peak in the area between 10-30 nm with an average
size of 17nm, suggested that this peak represents free MgOCl 2 particles, meaning that the
liposomes contained MgOCl 2 particles and that it remained within the liposomes for 3-4
weeks days until the liposomes started degrading. This means that particles of lipids or
MgOCl 2 nanoparticles made a broader size distribution curve thus affecting the PId and
size distribution average values of the size distribution curve (figure 17).
More than one peak in the liposome size distribution curve was observed for the
MgOCl2-immunoliposomes after 10 days of storage at 4 C.

The short life of the

MgOC12-immunoliposomes is related to an increase in antibody instability after dilution.
Antibodies become unstable after dilution, which in turn makes them oxidize, the
oxidation of the antibody may have made liposome degradation hastened. A technical
resource article written by Thermo Scientific Company Pierce Products, suggests to add a
carrier protein or a filler protein, like Bovine Serum Albumin, to the diluted antibody to
protect it against degradation (Pierce 2005). The addition of the filler protein, a protein
stabilizing cocktail or a cryoprotectant agent to the MgOCl 2 -immunoliposomes should
increase their shelf life, but more studies need to be performed in order to determine the
effect of the addition of these agents on the effectiveness of MgOCl 2-immunoliposomes
as a bactericidal agent.
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A BCA assay standard curve was used to determine the total protein concentration

present in the Antibody-Streptavidin complex which attaches to the surface of the
liposome after the dilutions and purification. The theoretical concentration of antibody
after dilutions was of 90.0 pg/ml and after the purification the total concentration of the
Streptavidin-antibody complex obtained was 44.2 pg/ml. A ratio of 1:1 of StreptavidinAntibody complex to MgOCl 2 liposomes was used to develop the immunoliposome, and
the concentration of Streptavidin-Antibody in the liposome solution was approximately
22.1 pg/ml. This low concentration might be the cause of the low reduction percentage
concentration and given the results obtained for the reduction percentages of the bacteria
treated with the MgOCl 2 immunoliposomes a higher concentration of antibody and
Streptavidin should be tested in order to find the Streptavidin-Antibody concentration
that will give optimum results for bacterium targeting.
The results from the Minimum Inhibitory Concentration assay for B. thuringiensis
(figure 21) showed that after a period of 22 hours of bacterial incubation with the
MgOCl 2 , drug concentrations of 2.0 M, 1.0 M, 0.5 M, and the MgOCl 2 liposomes caused
an absolute bacterial growth inhibition.

The control plate (HEPES) and MgOC

2

of

30mM and lower showed bacterial growth after the 22 hours period. The importance of
these results is the observation of an absolute bacterial growth inhibition caused by the
MgOCl 2 liposomes after the 22 hours of incubation.
Bacillus thuringiensiswas incubated with the liposomes to determine the growth

inhibition percentage of the bacteria in contact with the liposomes at three different
times- 0, 1, and 2 hours in the Colony Growth Assay (CGA).

The highest average

reduction percentage (58%) of B. thuringiensis was obtained after 1 hour of incubation
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with MgOCl 2 liposomes.

The statistical analysis also revealed that the reduction

percentage was significant in comparison with the controls (HEPES

and Empty

liposomes). The drug concentration inside the liposomes remains unknown. Assuming a
25% drug encapsulation efficiency, the approximated drug concentration of these
liposomes was 0.75 mM and the reduction percentage obtained from the bacteria
incubated with the 3 mM MgOCl 2 free drug was smaller than the reduction obtained for
the MgOCl 2 liposomes.

This suggests that the MgOCl 2 liposomes contributed to the

MgOCl 2 delivery through the membrane cell wall of the bacteria, causing a higher
bacterial reduction within 1 hour. Empty liposomes caused the 2 nd highest bactericidal
effect, at time 1 hour, this result showed statistical significance in the t-test performed.
The average of the bacterial reduction percentage of the empty liposomes increased due
to the reduction percentage of test #3 (see table3). The high bacterial reduction caused by
the empty liposomes on that particular test could be due to an unexpected degradation of
the empty liposomes or a change in pH in the empty liposomes solution, causing
cytotoxicity to B. thuringiensis cells. The average bacterial reduction effect caused by
MgOCl 2-immunoliposomes was lower than the effect of MgOCl 2 liposomes, since test #1
and #4 showed no bacterial reduction effect. There are several reasons that can explain
the low bacterial reduction caused by the MgOCl 2 immunoliposomes, random orientation
of the antibodies may have cause lower specificity and lower reduction.

Also, the

functionality of the antibody may have been affected after the Streptavidin-antibody
complex attachment to the liposomes. It is necessary to perform a functionality test on
the MgOCI2-immunoliposomes in order to determine if the low reduction percentages
obtained with the MgOCl2-immunoliposomes is due to the lost of functionality of the
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antibody. Free MgOCl2 (3mM) drug did not show a bacterial reduction in 3 of the 4 tests
performed, this suggests that 3mM of free MgOCl 2 is not a sufficient amount to cause a
bactericidal effect to B. thuringiensisin 1 hour of treatment.

In the CGA the highest bacterial reduction effect at 2 hours of incubation was
caused by the empty liposomes.

The high average reduction percentage in the empty

liposomes is the result of the high reduction percentage observed on tests #1 and #4. Due
to the high variability obtain within each test in the CGA, a test like a fluorescenceactivated cell sorter (FACS) should minimizes the experimental error and should be used
in future studies for a better quantification of the bactericidal effect of the MgOCl 2

liposomes and MgOCl 2-immunoliposomes. Halwani, used FACS to confirm interactions
of liposomes with bacterial membranes, and it would be practical for the confirmation of
the efficacy of the bactericidal effect for the application in this research (Halwani,
Mugabe et al. 2007). In order to get into additional conclusions with a CGA, a larger
population of samples should be used to obtain statistical results with smaller variability
values.
The bactericidal effectiveness of the MgOCl 2 liposomes observed in the CGA was

better for the treatment of B. thuringiensis after 1 hour of incubation than after 2 hours.
This result was because the bacteria that remained alive after the 1St hour of incubation
kept on replicating in the

2 "d

hour of incubation; therefore, the reduction percentage

diminished. This means that MgOC

2

liposomes are capable of affecting the cell wall of

the bacteria, but the concentration of MgOCl 2 inside the liposomes is not sufficient to
exterminate all the bacterium present in the solution in a period of 2 hours. Better results
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would have been obtained if the cells were incubated only with MgOCl 2 liposomes,
instead of in a 1:1 ratio of MgCl 2 liposomes to bacterial solution in LB broth.

It is stated in the product information sheet of Meridian Science Co. that the
rabbit anti-Bacillus spores antibody used to make the MgOCl2-immunoliposomes are
reactive with B. cereus and B. subtilis spores and vegetative cells, but the antibody can
cross-react with other Bacillus species. The MgOCl 2-immunoliposomes incubated with

B. thuringiensis showed a lower average reduction percentage than the MgOCl 2
liposomes. These results can be due to the presence of the antibody on the surface of the
liposomes, since the antibody attached to the surface of the liposomes is not against B.
thuringiensis a lower interaction between liposomes and the membrane of the bacteria

was observed. The low bactericidal reduction observed for the immunoliposomes could
be due to a small cross-reaction of B. thuringiensiswith the antibody on the liposomes or
the production of a small quantity of B. thuringiensisCryA toxins which cause liposomal
membrane permeation promoting the MgOCl 2 release (Du 2005).

Also, the low

bactericidal effect could be due to the lost of functionality in the antibody after the
crosslinking reaction with the Streptavidin and after linking it with the liposomes. For
the future use of this MgOCl 2-immunoliposome to detect only B. anthracis,a monoclonal
antibody specific for the B. anthracis poly-D-y-glutamic acid capsule, will be the best
choice.
The live/dead assay results demonstrated statistically significant reduction rates of
B.

thuringiensis compared

to

HEPES

at

1

hour of incubation,

with

MgOCl 2-

immunoliposomes and MgOCl 2 liposomes, with averages reduction percentages of 29.7
and 31.7 respectively. The p value of the MgOCl 2 liposomes (0.014) is larger than the p
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value of the MgOCl 2 -immunoliposomes

(0.0017),

this states that the reduction

percentages observed for the MgOCl 2-immunoliposomes is statistically more significant
than the reduction percentage of the MgOCl 2-liposomes, due to a higher variance
observed in the MgOCl 2 -liposomes.

The free MgOCl 2 at concentration of 3mM also

showed a statistically significant reduction percentage with a p value of 0.036. This p
value is large compared to the p values of MgOCl2-immunoliposomes and MgOCl 2-

liposomes due to the lower average reduction percentage observed in B. thuringiensis
treated with the free MgOCl 2 and due to a high variability between the samples. The
statistical analysis and the reduction percentages caused by the aforementioned liposomes
compared to the HEPES (control) suggests that MgOCl 2 liposomes and MgOCl 2
immunoliposomes are better bactericides for B. thuringiensis than 3mM of MgOCl 2 .
Since the encapsulation percentage of the liposomes is 25 %, the concentration of
MgOCl 2 within the MgOCl2-liposomes and MgOCl 2-immunoliposomes is lower than
3mM. The statistical analysis performed to compare the effect of empty liposomes with
MgOCl 2 liposomes (p value 0.00055), MgOCl 2 immunoliposomes (p value 0.016) and
3mM MgOCl 2 (p value 0.037), showed significant reduction percentages for the 3
aforementioned solutions. In this comparison free 3mM MgOCl 2 showed a significant
reduction percentage but its average reduction percentage compared to the MgOCl 2
liposomes and MgOCl 2 immunoliposomes is lower.
The live/dead assay for B. thuringiensis suggests that the MgOCl2-liposomes and
MgOCl2-immunoliposomes were effective in the drug transportation to the bacteria; this
result suggests that a higher bactericidal effect can be accomplished if a higher drug
concentration is encapsulated within the liposomes.
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In order to make sure that an

interaction between the bacteria and the liposomes is actually taking place some signaling

assays can be performed such as Atomic Force Microscopy (AFM) or Transmission
Electron Microscopy (TEM) can be used to observe the damage on the membrane cell
wall of the bacteria caused by the liposomes.
In the live/dead assay comparing the effect of the empty liposomes at time 0 hours
compared to 1 hour, the empty liposomes had no harmful effect on the B. thuringiensis
cells, supporting the hypothesis that the empty liposomes have a minimum effect in
bacterial cells cytotoxicity (see appendix J for statistical analysis). This result supports
the need of additional experiments to abandon the suspicion of empty liposomes
cytotoxicity observed in the colony growth after two hours of empty liposomes
incubation with bacterial cells.
B. subtilis live/dead assay average reduction percentages after 1 hour of
incubation for the MgOCl 2 liposomes and MgOCl2-immunoliposomes were 45.56 and
34.4 respectively.

Statistical analysis comparing the effect of HEPES vs. MgOCl 2

liposomes and MgOCl 2-immunoliposomes showed significant bactericidal effects only in
the MgOCl 2 liposomes (p value 0.0065). The non-significant reduction percentage result
observed for the immunoliposomes compared to the HEPES is due to a low bacterial
reduction percentage observed in test #2 where the reduction percentage of HEPES is
similar to the reduction percentage caused by the MgOCl 2-immunoliposomes.

The

statistical analysis observed comparing the effect of empty liposomes at 1 hour compared
to the MgOCl 2 liposomes

and MgOCl2-immunoliposomes

showed a statistically

significant reduction percentage for both solutions suggesting that they acted as good
drug carriers for B. subtilis.
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The higher reduction percentages obtained for the treatment of B. subtilis with
MgOCI2-immunoliposomes

compared to the effect of the immunoliposomes for B.

thuringiensis are due to the detection of the antibody attached to the surface of the

liposome by the antigens in B. subtilis, this identification caused the better drug release
than immunoliposomes with B. thuringiensis. Moreover, a higher reduction percentage
was observed for the treatment of B. subtilis with the MgOC12- liposomes. This might be
caused by a higher sensitivity of B. subtilis to the drug, and suggests that the

immunoliposomes should be improved by the addition of a higher concentration of the
Streptavidin-Antibody complex in order to obtain better reduction percentages results
caused by the MgOCl 2-immunoliposomes. A higher reduction percentage caused by the
MgOCl2-immunoliposomes incubation with B. subtilis was expected.

The antibody

attached to the surface of the liposomes is against the bacterium B. subtilis and B. cereus

the unexpected low reduction percentage caused by the MgOCl 2-immunoliposomes could
be due to a lost in functionality of the antibody in the crosslinking procedure.
The results obtained in this test for B. cereus showed a similar reduction
percentage and statistically non significant, between the bacteria treated with HEPES
buffer; empty liposomes; MgOCl 2 liposomes; MgOCl2-immunoliposomes (30.5; 30.7;
30.4; and 30.2 respectively). This result could be due to a low pH of the HEPES buffer
and the presence of hydrogen peroxide due to light exposure of the buffer.

In a study by Hamouds 1999, they investigated the sporicidal properties of 2
antimicrobial lipid emulsions, in order to eliminate human toxicity caused by the
sporicidal agents by itself. In this study, they observed a high sporicidal effect (98%) on
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B. cereus and B. subtilis caused by the lipid nanoemmulsions after 4 hours of treatment.
In the same study they used transmission electron microscopy (TEM) to observe

the physical damage in the bacterial spores caused by their nanoemmulsion (Hamouda,
Hayes et al. 1999).

The use of TEM would be a good approach to corroborate the

MgOCl 2 liposomes and MgOCl2-immunoliposomes interaction with the membrane cell

wall of the Bacillus bacterium studied in this thesis.
To my knowledge, this is the first study that applies nano-liposome technology to
encapsulate MgOCl 2 with the purpose to be treated as a bactericidal agent.

Previous

studies performed by Stoimenov group with free MgOCl 2 nanoparticles used as a
bactericidal agent for the treatment of E. coli, B. megaterium and B. subtilis, showed
promising results of the effect on this nanoparticles as a disinfectant. In this particular
study AFM imaging and TEM imaging was used to observe the nanoparticles effect on
the bacteria. It showed a strong and fast effect on the killing influence of the MgOCl 2
nanoparticle effect on the killing action of both bacterial cells and spores (Stoimenov
2002). In the research perfomed by Stoimenov (2002) no reduction percentages of
bacteria caused by the presence of MgOCl 2-particles were calculated.
With the purpose of applying the MgOCl 2 nanoparticles as biowarfare defense
agent, to increase the intracellular drug concentrations through fusion with bacterial cells
membranes, MgOCl 2 was encapsulated in liposomes. The attempt of a quantification of
its bactericidal effect was performed in our studies.

The tendency on the bactericidal

effect caused by the MgOCl 2 liposomes toward B. subtilis and B. thuringiensis coincides
with the results that Stoimenov group obtained in the treatment of B. megaterium and B.
subtilis with free MgOCl 2 nanoparticles.

Low MgOCl 2 concentrations encapsulated
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within the liposomes caused better reduction percentages
concentrations.

than higher free drug

The obtained results are promising, since low concentrations of

encapsulated MgOCl 2 within the liposomes caused some bactericidal effect within 2
hours. However, the system has room for improvement, if a higher drug concentration

could be encapsulated in the liposomes higher reduction percentages can be achieved in a
smaller amounts of time.

Also, the functionality of the antibody attached to the

liposomes has to be tested in order to determinate the MgOCl2-immunoliposomes
specificity, in a study by Schnyder 2004, they used immunocytochemistry

and

determined the cellular uptake of an antibody in a Streptavidin-antibody complex
(Schnyder, Krahenbuhl et al. 2004).

For better accuracy in the quantification of the

reduction percentages caused by the bacteria a Fluorescence Activated Cell Sorting

(FACS) system is highly recommended, also methods such as AFM or TEM can be used
to observe the damage on the membrane cell wall of the bacteria caused by the
liposomes.
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6.0 CONCLUSION
In this thesis, liposomes of average size of 130-90 nm were developed, with a
shell life of 15 days. The liposomes were modified with a polyclonal antibody against
the Bacillus cereus and Bacillus subtilis antigens.

The drug delivery efficacy of both

liposomes was tested in two different forms, a colony growth assay (CGA) and a
Live/Dead assay.
The bacterial viability of B. subtilis and B. thuringiensis tested using a live/dead
assay revealed that bacterium treated with the MgOCl 2 liposomes experienced a
statistically significant reduction percentage, compared to HEPES and empty liposomes,
with average reduction percentages of 45.6 and 31.7 respectively.

The results of the

bacteria B. cereus in the live/dead assay did not show a statistically significant

bactericidal effect of the liposomes.

MgOCl 2 immunoliposomes showed a lower

bactericidal effect toward the bacterium cells, compared to the MgOCl 2 liposomes
bactericidal effect, this could be due to a lost of functionality during the crosslinking
procedure of the antibody to the liposomes.

Immunocytochemistry tests, as well as

competition and uptake experiments, should be performed to corroborate the antibody
functionality after the crosslinking procedure.
The results of the CGA, revealed a statistical significant bacterial reduction
percentage for the MgOCl 2 liposomes at time 1 hour compared to HEPES and empty
liposomes. At time 2 hours the CGA revealed a statistical significant bacterial reduction
percentage for the MgOCl 2 liposomes compared with HEPES.

Non-statistically

significant bactericidal results were observed for the MgOCl 2 -immunoliposomes.
non-statistically significance

observed

in the bactericidal effect
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The

of the MgOCl 2 -

immunoliposomes is due to a low bactericidal effect observed in the CGA compared to

the HEPES and empty liposomes.

Finally, empty liposomes caused a high average

reduction percentage since 2 of the 4 tests performed revealed 100 % of bactericidal
effect. Due to the high variability observed in the CGA test, further conclusions cannot
be drawn regarding to the MgOCl 2 liposomes efficacy, what can be pointed is that the
MgOCl 2-liposomes showed the highest bacterial reduction in each of the tests, compared
to the MgOCl2-immunoliposomes and 3mM MgOCl 2 free drug.
The results presented in this thesis reveal a tendency of MgOCl 2 liposomes as a
bactericidal agent for B. thuringiensis and B. subtilis, suggesting this is an effective
bactericidal agent.

Lower reduction percentages

were caused by the MgOCl 2-

immunoliposomes compared to the MgOCl 2 liposomes.
In order to obtain better bacterial targeting effect a monoclonal antibody with a
concentration higher than 44.2 yg/ml of the Streptavidin-Antibody complex should be
attached to the liposome surface. Further research is still necessary to improve the drug
encapsulation efficiency; also for the corroboration of the efficacy of the MgOCl 2
liposomes and MgOCl2-immunoliposomes compared to the empty liposomes. In addition
the determination of the exact mechanism of MgOCl 2 -liposomes and MgOCl 2 immunoliposomes between the liposomes and the membrane cell wall of the bacteria is
recommended in order to further improve this drug delivery system.

Moreover,

additional studies such as Fluorescent Activated Cell Sorting (FACS), Atomic Force
Microscopy (AFM), and Transition Electron Microscopy (TEM) are recommended in
order to confirm liposome interactions with the bacterial membrane.
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APPENDIX
Appendix A. Liposome development

1.
2.

3.

4.
5.
6.
7.
8.
9.
10.
11.

Weight 87.5 mg of Phosphatidylcholine, 37.5 mg of PEG 2000 Biotin, and 6.5 mg
of Cholesterol.
Place the weighted lipids in a round bottom flask and add 50 ml of chloroform in
the chemical hood. Mix the lipids with the chloroform until no particles can be
observed.
Put a piece of parafilm around the neck of the flask before removing the flask
form the hood. Place the flask in the water bath of the rotovapor at 40 C, turn on
the vaccum, set the flask rotation 155 RPM, and wait one hour for the chloroform
to completely evaporate.
After the film is made take the round bottle from the rotovapor, use a kimwipe
and an elastic rubber to cover the neck of the flask.
Dip the flask 3 times in liquid Nitrogen.
Place the round bottom flask in the lyophilizer flask and leave it in the lyophilizer
over night.
After the overnight lyophilization, remove the flask from the lyophilizer and add
35 ml of 1M pH7 HEPES buffer.
Set the water bath of the rotovapor to 40 C and the circulator to 14*C.
Put the flask in the rotovapor at 100 RPM for 45 minutes verify that there is no
film attached to the bottom of the flask.
Weight 12.5mg of MgOCl 2 in the scale and add it to the liposome solution.
Place the liposome solution on the rotovapor at the same conditions mentioned on
step 8 and wait 15 minutes.

Appendix B. Liposome extrusion protocol
1.

Clean the 100 mL extruder parts with HEPES before adding the liposome
solution in it.
2. Connect the pressure "pipe" with the extruder.
3. Place the supporter and the 100 nm membrane filter in the tank.
4. Make an extrusion with 10 ml of HEPES to remove any residual particles from
the extruder.
5. Add 15 mL of the liposomes into the extruder.
6. Open the Argon tank and increase the pressure to 100 psi, open the valve that
connects the tank with the extruder (green valve) and close the release pressure

valve (black valve), keep on increasing the pressure until liposomes start coming
out of the extruder. If the liposomes stop from getting out of the extruder increase

the pressure 100 psi until the batch of liposomes is completely extruded.
7. Repeat this extruding procedure five times.
8. After the fifth time change the membrane filter and add 2ml of 2% Trehalose
3mM HEPES. Repeat step 7 and 8 for a total of 15 extrusions.
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9. Change the membrane filter to 80 nm and repeat steps 7 and 8. Add 1 ml of 10%

Trehalose 3mM solution after every five extrusions, before changing the filter.
10. Measure the liposome size in the nanosizer. If the size of the liposomes is in the
range of 120 to 100 nm the liposomes are ready for purification, if not the
extrusion procedure will be repeated with a 50 nm membrane filter.
11. To prepare the Sephadex G-50 weight 25 g of Sephadex.
12. Add 250 ml of HEPES to the 25 g of Sephadex.
13. Let the mix swell at room temperature for 3 hours or at 90"C for one hour.
14. While waiting for the Sephadex to swell, place some glass wool in HEPES
buffer.
15. When the Sephadex is swelled cut some of the glass wool and place it inside a 10
ml syringe, and fill the syringe with swelled sephadex-G50 to the 7m1 mark.
16. Place the column in a 50 ml plastic flask and place it in the centrifuge to spin for
3 minutes at 1000g.
17. Place 2.5 ml of MgOCl 2 liposomes in the column and place the column inside a
50 ml plastic flask.
18. Spin the columns containing the liposomes for 10 minutes at 50g, and for 3
additional minutes at 1000g.

Appendix C. Synthesis of Streptavidin- antibody complex
Vortex the antibody for 30 seconds. Dilute it in 2 ml of 1 M HEPES pH 7.
Dissolve 1 mg of TRAUTS reagent into 200 l of HEPES.
Add a 40:1 molar excess TRAUTS:Antibody.
Place it in a stirred water bath at room temperature for one hour.
Purify the complex in a Sephadex G-25 column, previously prepared.
In order to prepare the MBS dissolve 3.14 mg of MBS into lmL of DMSO
Vortex the streptavidin nanobeads for 30 seconds.
Dilute 40 l of Streptavidin in 5.0 ml of 16.0 mM of HEPES buffer.
Add a 40:1 molar excess of MBS:Streptavidin by adding 200 pl of MBS to 40 l
of diluted Streptavidin.
10. Mix 150 l of Streptavidin- MBS complex with 500 l of Trauts-Antibody.
11. Gently stir the mixture overnight in a water bath at room temperature.
12. Add a 1:1 ratio of liposomes and Streptavidin-Antibody complex, stir it in a water

1.
2.
3.
4.
5.
6.
7.
8.
9.

bath for 1 hour at room temperature.
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Appendix D. BCA assay enhanced protocol
1.

Pipette 25 pl of each standard or unknown sample replicate into a microplate 96
well plate.

2. Add 200 pl of the working reagent (WR) to each well and mix plate thoroughly
on a plate shaker for 30 seconds.
3. Cover plate and incubate at 60"C for 30 minute.
4. Cool plate to room temperature (RT) for 30 minutes.

5. Measure the absorbance at 595 nm on a plate reader.

Appendix E. Bacterial preparation
1. The bacteria is located at -80"C freezer, remove the bacteria from the freezer and
thaw, by rubbing the vial in your hands for 1 minute.
2. Streak the bacteria in a Luria Bertani agar Petri dish and incubate overnight at
physiological conditions.
3. Select an isolated colony for inoculation in lOml of LB broth in a shaking
incubator at physiological conditions overnight.
4. Dilute the overnight culture and measure its absorbance in a spectrophotometer at
600nm.

Appendix F. Colony growth assay
1. Make a 1:10 dilution of the overnight inoculated culture five times for a
concentration of (1x10 5 cells/ml). Make an OD 600 nm abosorbance measurement.

2. Mix well 500 l of the diluted bacteria with 500 l of HEPES buffer in vial 1.
3. Repeat step 2 for Empty liposomes, MgOCl 2 liposomes, MgOCl 2immunoliposomes, and 3mM MgOCl 2.
4. In a previous identified LB agar plate add 100 l of the corresponding well mixed
solution prepared on step 2 and 3 at time 0 hours, place the vials in a shaking
incubator at physiological conditions. Place the plates in the incubator at the same
conditions (do not shake the plates).
5. After one hour of incubation, remove the vials from the incubator and repeat step.
6. Place the vials in the shaking incubator at physiological conditions. Place the
plates in the incubator at the same conditions (do not shake the plates).
7. After two hours of incubation, remove the vials from the incubator and repeat step
8. Let the plate incubate for a period of 8 hours, in the incubator. The colonies
should be visible at this time, and count the colonies formed.
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Appendix G. Colony growth assay pictures
Colony Growth assay pictures, Test 2

3

3

1

1

2

,

(A)

(B)

Figure 23. Bacillus thuringiensis colony growth assay (A) Colony growth assay for B. thuringiensis
after 1 hour treatment with MgOCl 2 solutions, incubated overnight, where (1), is B. thuringiensis in

HEPES,
(2), is B. thuringiensis in Empty liposomes, (3), B. thuringiensis in MgOCl2
immunoliposomes, (4) is B. thuringiensis in MgOCl 2 liposomes, and (5), is B. thuringiensis in 3mM
MgOCl2 solution (B) Colony growth assay for B. thuringiensis after two hours of treatment with
MgOCl 2 solutions, incubated overnight. Observe the reduction of CFU's in plate number 3.

Colony Growth Assay Pictures, Test 3
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1

2

(B)

(A)

Figure 24. Bacillus thuringiensis colony growth assay (A) Colony growth assay for B. thuringiensis
after 1 hour treatment with MgOCl2 solutions, incubated overnight, where (1), is B. thuringiensis in
HEPES,
(2), is B. thuringiensis in Empty liposomes, (3), B. thuringiensis in MgOCl2

immunoliposomes, (4) is B. thuringiensis in MgOCl 2 liposomes, and (5), is B. thuringiensis in 3mM
MgOCl2 solution (B) Colony growth assay for B. thuringiensis after two hours of treatment with
MgOCl 2 solutions, incubated overnight.
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Appendix H. Live/Dead assay protocol (adapted from Invitrogen protocol)
1.

2.
3.
4.
5.

Concentrate 10 ml of the overnight culture in a centrifuge at 1 O,000X g for a

period of 15 minutes.
Remove the supernatant and resuspend the pellet in 10 ml of .85% of NaCl
Separate the resuspended 10 ml of cell solution into 5 flasks
Centrifuge the solution at 10,000X g for a period of 15 minutes.
Remove the supernatant of each vial and resuspend the pellet in 1 ml of HEPES,
empty liposomes, MgOCl 2 liposomes, MgOCl 2- immunoliposomes and 3mM
MgOCl 2 respectively

6.

Adjust the cell concentrations to 1 x108 cells/ml

7.
8.
9.
10.
11.

Prepare a mixture of 10 id of component A with 10 l of component B
Add 3 l of the dye mixture for each ml of bacterial suspension
Mix thoroughly and incubate in the dark for 15 minutes
Trap 5 l of the stained solution between a slide and a 18 mm square cover slip
Observe the bacteria under the microscope using a 40X lens with the appropriate
filter in order to see the stained bacteria.

Appendix I. Two paired t-test results for Bacillus thuringiensis, colony growth

assay.
Bacillus thuringiensisincubated with HEPES buffer reduction percentages ( i)
compared to the reduction percentages of Bacillus thuringiensisincubated with
Empty Liposomes (2)
Two paired t-test for pL1 p2 Ho=pti2
t-Test: Paired Two Sample for Means
Variable 2
Variable 1
2

0
0

36.2
30.3

Mean
Variance

0
0

47.0502978
1660.05595

0

78

Observations

8

8

0

31.9

Pearson Correlation

#DIV/0!

0

100

Hypothesized Mean
Difference

0

0

0

Df

7

0

0

T Stat

-3.266224

0

100

P(T<=t) one-tail

0.0068729

T Critical one-tail

1.8945775

P(T<=t) two-tail

0.0137458

T Critical two-tail

2.3646226

Table I-1 B. thuringiensis incubated with HEPES buffer CGA
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Bacillus thuringiensisincubated with HEPES buffer reduction percentages ( ,) compared
to the reduction percentages of Bacillus thuringiensisincubated with MgOCl2 liposomes
(p3).

Two paired t-test for p bp3 Ho=pI=p 3

1

t-Test: Paired Two Sample for Means
Variable 2
Variable 1

113

0
0
0

57.8
55.06
80

Mean
Variance
Observations

0
0
8

0

38.0

Pearson Correlation

#DIV/0!

0

26.5

Hypothesized Mean
Difference

0

0

60.3

Df

7

0
0

40
33.8

t Stat
P(T<=t) one-tail

-7.915946
4.875E-05

t Critical one-tail

1.8945775

P(T<=t) two-tail
t Critical two-tail

9.75E-05
2.3646226

48.9429568
305.819196
8

Bacillus thuringiensis incubated with HEPES buffer reduction percentages ( ,) compared

to the reduction percentages
immunoliposomes ( 4).
Two paired t-test for

of Bacillus thuringiensis incubated

with MgOCl 2

t-Test: Paired Two Sample for Means

I p 4 Ho=i =p 4

1

Variable 1

Mean

4

Variable 2

0
0

0
20.8

Variance
Observations

0
0

21.1295646
626.813714

0

52.3

Pearson

8

8

0

0

Hypothesized

0

0

0

57.7

T Stat

7

0
0

38.3
0

P(T<=t) one-tail
T Critical one-tail

-2.387076
0.0241881

P(T<=t) two-tail

1.8945775

T Critical two-tail

0.0483762

Correlation

#DIV/0!

Mean Difference

0

Df

2.3646226
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Bacillus thuringiensis incubated with empty liposomes reduction percentages

(p 2)

compared to the reduction percentages of Bacillus thuringiensis incubated with MgOCl 2
liposomes ( 3).
Two paired

t-Test: Paired Two Sample for Means, for p2#p3

t-test

Ho=p2=p3

Variable 1

Variable 2

Mean
Variance
Observations

47.050298
1660.0559
8

48.9429568
305.819196
8

38.0

Pearson correlation

-0.235225

26.5

Hypothesized Mean

0

2
36.2
30.3
78

57.8
55.06
80

31.9

100

3

Difference

0
0
100

60.3
40
33.8

Df
t Stat
P(T<=t) one-tail
t Critical one-tail

7
-0.111597
0.4571378
1.8945775

P(T<--t) two-tail

0.9142757
2.3646226

t Critical two-tail

Bacillus thuringiensis incubated with empty liposomes reduction percentages (2)

compared to the reduction percentages of Bacillus thuringiensis incubated with MgOCl2
immunoliposomes (y4)

Two paired

for p49p2 Ho=p4=p2

Variable 1

Variable 2
21.1295646
626.813714
8

t-test

p2
36.2
30.3

p4
0
20.8

Mean
Variance
Observations

47.050298
1660.0559
8

78

52.3

Pearson Correlation

-0.453836

31.9

0

Hypothesized Mean

0

Difference

100

0

Df

7

0

57.7

t Stat

1.2934604

0

38.3

P(T<=t) one-tail

0.1184481

100

0

t Critical one-tail

1.8945775

P(T<=t) two-tail

0.2368962

t Critical two-tail

2.3646226
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Bacillus thuringiensis incubated with empty liposomes reduction percentages (12)

compared to the reduction percentages of Bacillus thuringiensis incubated with 3mM
MgOC12 ().

Two paired ttest for p2#p5
Ho=p2=

t-Test: Paired Two Sample for Means

s

Variable 1

Variable 2

p2

15

36.2
30.3
78

0
0
32

Mean
Variance
Observations

47.050298 13.5520833
1660.0559 356.914559
8
8

31.9

0

Pearson Correlation

-0.483473

100

0

Hypothesized Mean

0

Difference

0

41.7

Df

7

0
100

34.8
0

t Stat
P(T<-t) one-tail

1.8030696
0.0571847

t Critical one-tail

1.8945775

P(T<=t) two-tail

0.1143694

t Critical two-tail

2.3646226
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Appendix J. Bacillus thuringiensis, live/dead assay t-test: paired two sample for
means
Bacillus thuringiensis, incubated with HEPES at time 1 hour (p 1,1) compared to B.

thuringiensis incubated with empty liposomes at 1 hour of incubation (p2,1), where
e

2 Ho=pi,1=p2,1

PI,1
8.7
10.7
25.3

2,1

7.7
18.7
31.1

Mean
Variance
Observations
Pearson Correlation
Hypothesized Mean

Variable 1
14.9
82.12
3
0.929222

Difference

Variable 2
19.16667
137.0533
3

0

Df

2

t Stat
P(T<=t) one-tail
t Critical one-tail

-1.57509
0.127957
2.919987

P(T<=t) two-tail

0.255915

t Critical two-tail

4.302656

Bacillus thuringiensis, incubated with HEPES at time 1 hour (p 1,1) compared to B.
thuringiensis incubated with MgOCl 2 liposomes at 1 hour of incubation (p3,1), where
1 p3 Ho=pi, 1=p3,1
11,1

p_,_

_

8.7
10.7

20.0
32.0

Mean
Variance

25.3

43.0

Observations
Pearson Correlation
Hypothesized Mean
Difference

Df

Variable 2

Variable 1

14.9
82.12

31.6667
132.333

3
0.90555

3

0

2

t Stat

-5.7337

P(T<=t) one-tail
t Critical one-tail

0.01455
2.91999

P(T<=t) two-tail

0.0291

t Critical two-tail

4.30266
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Bacillus thuringiensis, incubated with HEPES at time 1 hour (p1,1) compared to B.

thuringiensis incubated with MgOC
where 11 p4 Ho=1,i=p4 ,1
i1
8.7
10.7
25.3

p4,1
22.0
27.0
40.0

2

immunoliposomes at 1 hour of incubation (p4,1),

Mean
Variance
Observations
Pearson Correlation
Hypothesized Mean
Difference
Df
t Stat
P(T<-t) one-tail

Variable 1
14.9
82.12
3
0.98693

Variable 2
29.6667
86.3333
3

0
2
-17.038
0.00171

t Critical one-tail

2.91999

P(T<=t)

two-tail

0.00343

t Critical two-tail

4.30266

Bacillus thuringiensis, incubated with HEPES at time 1 hour (p 1,1) compared to B.
thuringiensisincubated with 3mM MgOCl 2 at 1 hour of incubation (p5,1), where 1 ps
Ho=1,i=p1
5,i

!1,1

I

Variable 2

Variable 1

s,1

8.7

13.0

Mean

14.9

26.3333

10.7
25.3

30.0
36.0

Variance
Observations

82.12
3

142.333
3

Pearson Correlation

0.77604

Hypothesized Mean
Difference

0

Df

2

t Stat

P(T<=t)

-2.631

one-tail

0.05959

t Critical one-tail

2.91999

P(T<=t)

two-tail

0.11918

t Critical two-tail

4.30266
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Bacillus thuringiensis, incubated with empty liposomes at time 0 hours (p12,0) compared

to B. thuringiensisincubated with empty liposomes at 1 hour of incubation (p.2,1), where
p2,o9p2,1 Ho=p2,o=p 2,1
t-Test: Paired Two Sample for Means
Variable

p2,

p2,1

4.3
20.7
19

7.7
18.7
31.1

Mean
Variance
Observations
Pearson Correlation
Mean
Hypothesized

1

14.6666667
80.7777778
3
0.79486676
0

Variable 2

19.14815
137.5844
3

Difference
Df

2

T Stat

-1.089383

P(T<=t) one-tail

0.19487609

T Critical one-tail

2.91998731

P(T<=t) two-tail

0.38975219

T Critical two-tail

4.30265573

Bacillus thuringiensis, incubated with empty liposomes at time 1 hours (p.2,1) compared
to B. thuringiensis incubated with MgOCl 2 liposomes at 1 hour of incubation (p.3,1),
where p2p3 Ho=p2,I=p 3 ,1

7.7

P3,1
20.0

18.7
31.1

32.0
43.0

2,1

Variable 2

Variable 1

Mean

19.1667

31.6667

Variance
Observations

137.053
3

132.333
3

Pearson Correlation

0.99822

Hypothesized Mean
Difference

0

Df

2

t Stat

-30.024

P(T<=t) one-tail

0.00055

t Critical one-tail

2.91999

P(T<=t)

two-tail

0.00111

t Critical two-tail

4.30266
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Bacillus thuringiensis, incubated with empty liposomes at time 1 hours (p2,1) compared
to B. thuringiensis incubated with MgOCl2 immunoliposomes at 1 hour of incubation
(p4, 1), where p2#Ip4 Ho=p 2 ,=94,1

F12,1
7.7
18.7
31.1

Variable 1
19.1667
137.053
3

4,1
22.0
27.0
40.0

Mean
Variance
Observations
Pearson Correlation

Variable 2
29.6667
86.3333
3

0.97662

Hypothesized Mean
Difference

0

Df

2

t Stat
P(T<--t) one-tail
t Critical one-tail

-5.5035
0.01573
2.91999

P(T<=t) two-tail

0.03147

t Critical two-tail

4.30266

Bacillus thuringiensis, incubated with empty liposomes at timel hour (p2,1) compared to
B. thuringiensis incubated with 3mM MgOCl 2 at 1 hour of incubation (p5,1), where
p2 ps Ho=p2=ps

7.7
18.7

1s,1
13.0
30.0

31.1

36.0

112,1

Variable 2

Variable 1

Mean
Variance
Observations
Pearson Correlation

19.1667
137.053

26.3333
142.333

3

3

0.95416

Hypothesized Mean
Difference

0

Df

2

t Stat
P(T<=t) one-tail
t Critical one-tail

-3.4623
0.03712
2.91999

P(T<=t) two-tail

0.07425

t Critical two-tail

4.30266
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Appendix K. B. subtilis, live/dead assay t-test: paired two sample for means

B. subtilis incubated with HEPES at time 1 hours (p 1,1) compared to B. subtilis
incubated with Empty liposomes at 1 hour of incubation (p4,1), where p p2
Ho=p1,1~2i

pi,1
20.0
23.0
26.0

p 2,1
28.9
18.0
23.0

Mean
Variance
Observations

Variable 1
23
9
3

Pearson Correlation

-0.54022

Hypothesized Mean
Difference
Df
t Stat

0
2
-0.06835

P(T<=t) one-tail

0.475862

t Critical one-tail

2.919987

P(T<=t) two-tail

0.951725

t Critical two-tail

4.302656

Variable 2
23.2963
29.70782
3

B. subtilis incubated with HEPES at time 1 hours (p 1,1) compared to B. subtilis
incubated with MgOCl 2 at 1 hour of incubation (p3,1), where p4p3 Ho=p ,=p3,I.
Variable 1

Variable 2

20.0

38.0

Mean

23

45.57881

23.0
26.0

45.7
53.0

Variance
Observations

9
3

56.26863
3

Pearson Correlation

0.999834

_1

p3,1

Hypothesized Mean
Difference

0

Df

2

t Stat

-8.68659

P(T<=t) one-tail

0.006497

t Critical one-tail

2.919987

P(T<-t) two-tail

0.012995

t Critical two-tail

4.302656
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B. subtilis incubated with HEPES at time 1 hours (p 1,1) compared to B. subtilis
incubated with MgOCl 2 immunoliposomes at 1 hour of incubation (p4,1), where p.l p4
Ho=pl,i=p4,I.

s
20.0
23.0
26.0

p41
37.5
25.0
40.8

Mean
Variance
Observations

Variable 1
23
9
3

Pearson Correlation

0.196785

Variable 2
34.42557
69.31516
3

Hypothesized Mean
Difference

0

Df

2

T Stat

-2.39133

P(T<=t) one-tail

0.069628

t Critical one-tail

2.919987

P(T<=t) two-tail

0.139255

t Critical two-tail

4.302656

B. subtilis incubated with empty liposomes at time 1 hours (p2,1) compared to B. subtilis

incubated with MgOCl 2 liposomes at 1 hour of incubation (p3,1), where p2#p3
Ho=p2,1=p3,I.
p2,1

;3,1

Variable 1

Variable 2

28.9

38

Mean

23.2963

45.57881

18.0
23.0

45.7
53.0

Variance
Observations
Pearson Correlation
Hypothesized Mean
Difference

29.70782
3
-0.55544

56.26863
3

0

Df

2

T Stat

-3.36694

P(T<-t) one-tail

0.039014

t Critical one-tail

2.919987

P(T<-t) two-tail

0.078028

t Critical two-tail

4.302656
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B. subtilis incubated with empty liposomes at time 1 hours (p2, 1) compared to B. subtilis
incubated with MgOC 2 immunoliposomes at 1 hour of incubation (p4,1), where p2#p4
Ho= 2,1=p4,1.

s2,1

28.9
18.0
23.0

P4,1
37.5
25.0
40.8

Variable 1

Variable 2

Mean
Variance
Observations
Pearson Correlation
Hypothesized Mean
Difference
Df
T Stat

23.2963
29.70782
3
0.718765

34.42557
69.31516
3

P(T<=t) one-tail

0.040077

t Critical one-tail

2.919987

P(T<=t) two-tail

0.080155

t Critical two-tail

4.302656

0
2
-3.31614

Appendix L. Bacillus cereus, live/dead assay t-test: paired two sample for means

B. cereus incubated with HEPES at time 1 hours (p 1,1) compared to B. cereus incubated
with empty liposomes at 1 hour of incubation (p2,1). where pli#p2 Ho=p1,r=p2,i.

P1,1
32.2
28.5

Variable 1

Variable 2

26.0
34.0

Mean
Variance

30.54333
3.597433

30.66667
17.33333

31.0

32.0

Observations

3

3

Pearson Correlation

-0.88182

21

Hypothesized Mean
Difference

0

Df

2

t Stat

-0.03618

P(T<=t) one-tail

0.487212

t Critical one-tail

2.919987

P(T<=t) two-tail

0.974424

t Critical two-tail

4.302656
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B. cereus incubated with HEPES at time 1 hours (pl,1) compared to B. cereus incubated

with MgOCl 2 liposomes at 1 hour of incubation (p3,1), where p 4p3 Ho=pl, 1=p3,l.
pi,

p3 1

32.2
28.5
31.0

34.6
27.7
29.0

Variable 1

Variable 2

Mean
Variance
Observations

30.54333
3.597433
3

30.43333
13.58173
3

Pearson Correlation

0.850641

Hypothesized Mean
Difference
Df
t Stat
P(T<--t) one-tail

0
2
0.082858

t Critical one-tail

2.919987

P(T<=t)

two-tail

0.941511

t Critical two-tail

4.302656

0.470755

B. cereus incubated with HEPES at time 0 hours (p 1,1) compared to B. cereus incubated
with MgOCl 2 immunoliposomes at 1 hour of incubation (p4,1) where pi44 Ho=p1,1=p4,1.

PI '

p4,1

32.2

38.0

Mean

Variable 1
30.54333

Variable 2
30.24667

28.5

32.7

Variance

3.597433

85.66253

31.0

20.0

Observations
Pearson Correlation
Hypothesized Mean
Difference
Df
t Stat
P(T<--t) one-tail
t Critical one-tail

3
0.077995

3

P(T<=t)

0
2
0.055242
0.480484
2.919987

two-tail

0.960968

t Critical two-tail

4.302656
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B. cereus incubated with empty liposomes at time 1 hours (p2,1) compared to B. cereus

incubated with MgOC12 liposomes

at 1 hour of incubation (p3,1) where p29p3

Ho=p2,I=p 3 ,l.
2,1

26.0
34.0
32.0

Variable 1

Variable 2

Mean
Variance
Observations
Pearson Correlation
Hypothesized Mean
Difference
Df
t Stat

30.66667
17.33333
3
-0.99805

30.43333
13.58173
3

,

34.6
27.7
29.0

0
2
0.051517

P(T<=t) one-tail

0.481798

t Critical one-tail

2.919987

P(T<=t) two-tail

0.963596

t Critical two-tail

4.302656

B. cereus incubated with empty liposomes at time 1 hours (p2,1) compared to B. cereus

incubated with MgOCl 2 immunoliposomes at 1 hour of incubation (p4,1), where
Ho=p2,I=p4,l.

Variable 1

Variable 2

26.0

38.0

Mean

30.66667

30.24667

34.0
32.0

32.7
20.0

Variance
Observations

17.33333
3

85.66253
3

Pearson Correlation

-0.53893

Hypothesized Mean
Difference

0

p2,1

_41

Df

2

t Stat

0.060511

P(T<=t) one-tail

0.478626

t Critical one-tail

2.919987

P(T<=t) two-tail

0.957252

t Critical two-tail

4.302656
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